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I. INTRODUCTION 
 
An ideal drug delivery system provides treatment for acute diseases or chronic 
illness to the patients for many years.  A number of oral dosage forms are available, 
some are liquids (e.g., syrups, elixirs, tinctures, suspensions, and emulsions), whereas 
the most common ones are solids (e.g., tablets and capsules). Tablets and capsules are 
generally formulated to release the drug immediately after oral administration to 
hasten systemic absorption. These are called conventional dosage forms. Usually 
conventional dosage form produce wide ranging fluctuation in drug concentration in 
the blood stream and tissues with consequent undesirable toxicity and poor efficiency. 
This factors as well as factors such as repetitive dosing and unpredictable absorption 
led to the concept of modified drug delivery system. The goal in designing modified 
delivery system is to reduce the frequency of the dosing or to increase effectiveness of 
the drug by localization at the site of action or reducing the dose required or providing 
uniform drug delivery. 1 
The term ‘Modified Release’ is used to describe products that alter the timing 
and/or the rate of release of the drug substance. The USP defines a modified drug 
delivery system “as one for which the drug release characteristics of time course or 
location of drug release, or both are chosen to accomplish objectives of therapeutic 
effectiveness or convenience not fulfilled by conventional dosage forms such as 
solution, ointments, or promptly dissolving dosage forms as presently recognized”.2  
 
1.1 TYPES OF ORAL DRUG DELIVERY SYSTEMS
3 
 Oral drug delivery systems (ODDS) are divided into 
  1. Immediate release drug delivery systems 
  2. Modified release drug delivery systems 
1.1.1) IMMEDIATE RELEASE DRUG DELIVERY SYSTEMS 
  Immediate release drug delivery systems are intended to disintegrate rapidly, 
and exhibit instant drug release. They are associated with a fast increase and decrease, 
and hence fluctuations in drug plasma levels, which leads to reduction or loss in drug 
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effectiveness or increased incidence of side effects. Administration of the drug 
delivery systems several times per day is therefore necessary to compensate the 
decrease in drug plasma concentration due to metabolism and excretion. 
  The limitations associated with such a conventional dosage form; 4 
 Poor patient compliance. 
 Difficult to achieve steady-state plasma concentration. 
 The unavoidable fluctuations in the drug concentration may lead to under- 
medication or over- medication. 
 The fluctuating drug levels may lead to precipitation of adverse effects 
especially of a drug with small therapeutic index.  
1.1.2) MODIFIED RELEASE DRUG DELIVERY SYSTEMS: 
Modified release systems, on the other hand, have been developed to improve 
the pharmacokinetic profiles of active pharmaceutical ingredients (APIs) and patient 
compliance, as well as reducing side effects. Modified drug delivery systems 
sophisticated and take into account pharmacokinetic principles, specific drug 
characteristics, and variability of response among individuals with different medical 
conditions. These systems are design to deliver drugs at a specific site or over a period 
of time after administration, or at a specific location of the body. Administration 
Modified release delivery systems may be divided conveniently in to four 
categories. 
A) Delayed release 
B) Extended release 
 i) Sustained release 
 ii) Controlled release 
C) Site specific targeting 
D) Receptor targeting. 
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A) Delayed Release 
These systems are those that use repetitive, intermittent dosing of a drug from 
one or more immediate release units incorporated into a single dosage form. 
Examples of delayed release systems include repeat action tablets and capsules and 
enteric-coated tablets where timed release is achieved by a barrier coating. 
B) Extended Release 
Oral Drug Delivery Systems allows the drug to be released over prolonged 
time periods. By extending the release profile of a drug, the frequency of dosing can 
be reduced.  Extended release can be achieved using sustained or controlled-release 
dosage forms.         
i) Sustained release 
These systems also provide a slow release of drug over an extended period of 
time and also can provide some control, whether this be of a temporal or spatial 
nature, or both, of drug release in the body, or in other words, the system is successful 
at maintaining constant drug levels in the target tissue or cells. 
 ii) Controlled release 
Dosage form is generally accomplished by attempting to obtain “zero- order” 
release from the dosage form which independent of the amount of drug in the delivery 
system (i.e., a constant release rate). Sustained Release systems generally do not attain 
this type of release and usually try to mimic zero order release by providing drug in a 
slow first order fashion (i.e., concentration dependent).      
C) Site specific targeting 
These systems refer to targeting of a drug directly to a certain biological 
location. In this case the target is adjacent to or in the diseased organ or tissue. 
D) Receptor targeting 
These systems refer to targeting of a drug directly to a certain biological 
location. In this case the target is the particular receptor for a drug within an organ or 
tissue. Site specific targeting and receptor targeting systems satisfy the spatial aspect 
of drug delivery and are also considered to be controlled drug delivery systems. 
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1.2 Oral Controlled release Drug Delivery systems
2, 5 
The oral route of drug delivery is typically considered the preferred and most 
patient-convenient means of drug administration. Consequently, much effort is 
directed during drug discovery to identify orally active candidates that will provide 
reproducible and effective plasma concentrations in vivo. The reality is that many 
compounds are either incompletely or ineffectively absorbed after oral administration 
(i.e., bioavailability is an issue), or that the required dosing frequency is too short to 
enable once- or twice-daily administration (i.e., pharmacokinetic half-life is an issue). 
Lead optimization typically addresses such shortcomings during a discovery program; 
however, in many cases it is not possible to identify an appropriate clinical candidate 
with the requisite “ideal” physicochemical and/or pharmacokinetic properties. For 
clinical research phase drug candidates, or drugs already marketed, the opportunity 
for enhancing their clinical pharmacology profile after oral administration through 
attainment of more optimal blood drug concentration-time profiles should always be 
considered. 
The development of a pharmaceutical product for oral delivery, irrespective of 
its physical form (solid, semisolid or liquid), involve varying extent of optimization of 
dosage form characteristics within the inherent constraints of gastrointestinal (GI) 
physiology.  
Oral controlled release drug delivery is thus a drug delivery system that 
provides the continuous oral delivery of drug at the predictable and reproducible 
kinetics for predetermined period throughout the course of gastrointestinal transit. 
Also included are systems that target the delivery of drug to a specific region within 
the gastrointestinal tract for either a local or a systemic action. For oral controlled 
administration of drugs, several research and development activities have shown 
encouraging signs of progress in development of controlled release dosage forms as 
well as in the search for new approaches to overcome the potential problems 
associated with oral drug administration. 
All the pharmaceutical products formulated for systemic delivery via the oral 
route of administration, irrespective of mode of delivery (immediate, sustained or 
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controlled release) and the design of dosage form (solid, dispersion or liquid) must be 
developed within intrinsic characteristic of gastrointestinal (GI) physiology. 
  1.2.1. Gastrointestinal Anatomy and Physiology 4,6,7,8 
Drug Absorption is defined as the process of movement of unchanged drug 
from the site of administration to systemic circulation. 
The oral route of drug administration is most common for systemically acting 
drugs and therefore, more emphasis will be given to gastrointestinal (GI) absorption 
of drugs. Drug administered orally is pass from various part of GI tract (stomach, 
small intestine, large intestine), which differ from each other in terms of anatomy, 
function, secretion and pH. 
 Stomach: 
The stomach is an organ with a capacity for storage and mixing. The stomach 
lining is devoid of villi but consist of considerable number of gastric pits that 
contribute to the storage capacity of stomach. 
Under physiological conditions, the gastric absorption of most drug is 
insignificant as a result of its limited surface area (0.1-0.2 m2) covered by a thick 
layer of mucus coating, lack of villi on the mucosal surface, and short residence time 
of most drugs in the stomach. Its acidic pH (1-3), due to secretion of HCl, favors 
absorption of acidic drugs if they are soluble in gastric fluid since they are unionized 
to the large extent in such a pH. The gastric pH aids dissolution of basic drugs due to 
salt formation and subsequent ionization which are therefore absorbed to a lesser 
extent from stomach because of the same reason.                                
 Small intestine:- 
It is the major site for absorption of most drugs due to its large surface area 
(200 m2). The folds in the intestinal mucosa, called as the folds of Kerckring, result in 
the three fold increase in surface area. The surface of these folds possess finger like 
projection called as villi which increase surface area 30 times. From the surface of 
villi protrude several microvilli resulting in 600 times increase in surface area.  Blood 
flow to the small intestine is 6-10 times that of stomach. Moreover, the pH range of 5-
7.5 is most favorable of most drugs to remain unionized. The peristaltic movement of 
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intestine is slow, transit time is long, and permeability is high. Thus, a Contribution of 
all the above factors make intestine best site for absorption of most drugs. 
Large intestine:- 
Its length and mucosal surface area is very small (0.15 m2) in comparison to 
small intestine and thus absorption of drugs from this region is insignificant. Its 
contents are neutral or alkaline. The main role of large intestine is in the absorption of 
water and electrolytes. However, because of the long residence time (6-12 hrs), 
colonic transit may be important in the absorption of some poorly drugs and sustain 
release dosage form. 
 Gastric emptying:-9 
It is the process of passage from stomach to the small intestine, can also be a 
rate limiting step in drug absorption because the major site for drug absorption is 
intestine. Thus, generally speaking, rapid gastric emptying increases bioavailability of 
drugs.  
 Gastric emptying of a drug is delayed by co-administrating food because 
unless the gastric content are fluid enough or the size of the solid particles is reduced 
below to 2 mm, its passage through the pylorus into the intestine is not possible.  
 For better absorption, the gastric emptying can be promoted by taking the 
drugs on empty stomach. 
 Gastro intestinal transit time :- 10,11 
Small intestine is the major site for absorption of most drugs, long intestinal 
transit time is desirable for complete drug absorption.  
Residence time depends upon the intestinal motility or contractions. The 
mixing movement of the intestine that occurs due to peristaltic contraction promotes 
drug absorption, firstly, by increasing the drug intestinal membrane contact, and 
secondly, by enhancing the drug dissolution especially of poorly soluble drugs. 
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Fig 1: Stomach. 
 
 
  
 
 
 
 
       
    
                                                                  
 
 
Fig 2:  Parts of Large Intestine. 
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 Table no. 1: APPROXIMATE pH AND TRANSIT TIME WITH IN THE 
GASTROINTESTINAL TRACT 
Part pH Transit time (Hours) 
Stomach 1.0-3.0 1-5 
Duodenum 4.0-6.5 5min 
Jejunum 5.0-7.0 2 
Ileum 6.0-8.0 3-6 
Caecum 6.0-8.0 0.5-1.0 
Colon 6.0-8.0 6-12 
Rectum 6.0-8.0 6-12 
1.3 SUSTAINED RELEASE CONCEPT
3, 5
Sustained release, sustained action, prolonged action controlled release, 
extended action , timed release, depot and repository dosage forms are terms used to 
identify drug delivery systems that are designed to achieve prolonged therapeutic 
effects by continuously releasing medication over an extended period of time after 
administration of single dose. 
  
 
 
    
 
 
Fig3: Drug level verses time profile showing differences between zero order, 
controlled release, slow first order sustained release and release from 
conventional tablet. 
Sustained release and controlled release will represent separate delivery 
processes; sustained release constitutes any dosage form that provides medication 
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over an extended period of time. Controlled release however, denotes that system is 
able to provide same actual therapeutic control, whether this be temporal nature, 
spatial nature or both .In other words, the system attempts to control drug 
concentration in target tissue. This correctly suggests that there are sustained release 
systems that cannot be considered as controlled release. 
 In general, the goal of sustained release dosage form is to maintain therapeutic 
blood level or tissue level of the drug for extended period. This is usually 
accomplished by attempting to obtain zero order release from the dosage form. Zero 
order release constitutes of the amount of drug in the delivery system(i.e.; a constant 
release rate).Sustained release systems generally don’t attain this type of release and 
usually try to – zero order release by providing drug in a slow first order fashion(i.e.; 
concentration dependent). 
 Oral ingestion has been the most convenient and commonly employed route of 
drug delivery. Indeed for sustained release systems, the oral route of administration 
has received the most attention with respect to research on physiological and drug 
constraints as well as designing and testing of products. 
 With most of orally administered drugs targeting is not primary concern, and it 
is usually intended for drugs to permeate to the general circulation and perfuse to 
other body tissues(the obvious exception being medication intended for local 
gastrointestinal tissue treatment),for this reason, most systems employed are of the 
sustained release  variety. It is assumed that increasing concentration at the absorption 
site will increase the rate of absorption and, therefore, increase circulating blood 
levels, which in turn promotes greater concentrations of the drug at the site of action. 
If toxicity is not an issue, therapeutic levels can thus be extended. 
 An alternative approach is to administer the drug repetitively using a constant 
dosing interval, as in multiple dose therapy. In this case the drug blood level reached 
and time required to reach that level depend on the dose and dosing interval. There are 
several potential problems inherent in multiple dose therapy. If the dosing interval is 
not appropriate for the biological half life of the drug, large peaks and valleys in the 
drug blood level may result. For example the drug with short half life requires 
frequent dosing to maintain constant therapeutic levels. The drug blood level may not 
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be within the therapeutic range at sufficiently early times, an important consideration 
for certain disease state. Patient non compliance with the multiple dosing regimen can 
result in failure of this approach. 
1.3.1 Rationale of sustained drug delivery 
12, 13
 
 The basic rationale for controlled drug delivery is to alter the pharmacokinetic 
and pharmacodynamics of pharmacologically active moieties by using novel drug 
delivery systems or by modifying the molecular structure and/or physiological 
parameters inherent in selected route of administration. It is desirable that the duration 
of drug action become more to design properly. Rate controlled dosage form, and less, 
or not at all, a property of the drug molecules inherent kinetic properties. 
 As mentioned earlier, primary objectives of controlled drug delivery are to 
ensure safety and to improve efficiency of drugs as well as patient compliance. This is 
achieved by better control of plasma drug levels and frequent dosing. For 
conventional dosage forms, only the dose (D) and dosing interval© can vary and, for 
each drug, there exist a therapeutic window of plasma concentration, below which 
therapeutic effect is in sufficient, and above which toxic side effect are elicited. This 
is often defined as the ratio of median lethal dose (LD50) to median effective dose 
(ED50)  
 
Fig 4:   A hypothetical plasma concentration-time profile from oral Sustained 
release dosage formulations. 
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Potential advantages of sustained drug delivery: 
1. Patient compliance due to reduction in the frequency of designing. 
a) Employ minimum drug 
b) Minimize or eliminates local and systemic side effects. 
c) Obtain less protestations or deduction in drug activity with chronic use. 
d) Minimize drug accumulation with chronic dosing. 
2. Improve efficacy in treatment. 
a) Cure or controlled confirm more promptly. 
b) Improve control of condition i.e.; reduce fluctuation in drug level. 
c)  Improve bioavailability of some drugs. 
d) Make use of special effects. 
     e.g.: sustained release aspects for morning. 
Disadvantages of sustained release dosage forms: 
a) They are costly. 
b) Unpredictable and often poor in-vitro in-vivo correlations, dose dumping, 
reduced potential for dosage adjustment and increased potential first pass 
clearance. 
c) Poor systemic availability in general. 
d) Effective drug release period is influenced and limited by GI residence 
time. 
 1.3.2 Classification of oral sustained/controlled release systems
14, 15 
A. Continues release systems 
1. Dissolution controlled release systems 
a) Matrix type             b) reservoir type 
         2. Diffusion controlled release systems  
a) Matrix type             b) reservoir type 
   3. Dissolution and diffusion controlled release systems 
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   4. Ion exchange resins drug complexes 
   5. Slow dissolving salts and complexes 
   6. pH dependent formulations 
   7. Osmotic pressure controlled systems 
   8. Hydrodynamic pressure controlled systems 
    B. Delayed transit and continuous release systems 
       1. Altered density systems 
I. High density 
II. Low density 
III. Floating 
      2. Muco- adhesive systems 
      3. Size based systems 
C. Delayed released systems 
1. Intestinal release systems 
2. Colonic release systems 
Diffusion controlled systems: 
The basic mechanism of drug release from these two systems is fundamentally 
different besides these simple systems, combination of reservoir and monolithic 
systems also exist in practice.        
 Diffusion systems are characterized by release rate of drug is dependant on its 
diffusion through inert water insoluble membrane barrier.  
There are basically two types of diffusion devices.  
I. Reservoir devices    
II. Matrix devices  
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• Reservoir Devices: 
 Reservoir Devices are those in which a core of drug is surrounded by 
polymeric membrane. The nature of membrane determines the rate of release of drug 
from systemThe process of diffusion is generally described by following equation. 
dMt/ dt =    ADK C/ d 

•    Matrix devices 
A matrix device, as the name implies, consists of drug dispersed 
homogenously throughout a polymer. Matrix diffusion system before release 
(time =0) & after partial drug release (time = t).  
 
 
 
 
   
 
In this model drug in outside layer exposed to the bathing solution is dissolved 
first and diffused out of the matrix.  This process continues with the interface 
between  bathing solution and the solid drug moving controlled, the rate of dissolution 
of drug particles within the matrix must be faster that the diffusion rate of dissolved 
drug leaving matrix. 
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Osmotic controlled release systems: 
Osmotic controlled oral drug delivery systems utilize osmotic pressure for 
controlled delivery of active ingredients. Drug delivery from these systems to a large 
extent is independent of physiological factors of the gastro intestinal tract and these 
systems is governed by various formulation factors such as solubility and osmotic 
pressure of the core component, size of the delivery orifice and nature of the rate 
controlling membrane. Drug release from this system is independent of pH and other 
physiological parameter to a larger extent and it is possible to modulate the release 
characteristics. 
1.3.3Factors Affecting Sustained Release Dosage Forms
16, 17

 The design of sustained release delivery system is subjected to several 
variables of considerable importance. Each of these variables is interrelated, and this 
imposes certain constraints upon choices for the route of delivery, the design of 
delivery systems, and the length of therapy. Of particular importance interest to the 
scientist designing the system are the constraints imposed by the properties of the 
drug. These properties have the greatest effect on the behaviors of the drug in the 
delivery systems and the body. 
             Factors governing the design of sustained /controlled release dosage forms. 
 A.  Physico chemical factors 
1. Aqueous solubility 
2. Partition coefficient 
3. Molecular size 
4. Drug Stability 
5. Protein binding 
6. Dose size 
B. Biological factors 
1. Absorption 
2. Distribution 
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3. Metabolism 
4. Elimination 
5. Duration of action 
6. Margin of safety 
7. Side Effects 
8. Diseased state 
A) PHYSICO CHEMICAL PROPERTIES 
a) Dose Size:  
In general, dose strength of 1.0g is considered maximum for a controlled 
release drug delivery systems. 
b) Aqueous Solubility: 
Most of drugs are weak acids or bases, since the unchanged form of a drug 
preferentially permeates across lipid membranes. Drugs aqueous solubility will 
generally be decreased by conversion to an unchanged form, for drugs with low water 
solubility will be difficult to incorporate into sustained release mechanism. The lower 
limit on solubility for such product has been reported 0.1mg/ml.  
c) Partition Coefficient: 
Partition coefficient is generally defined as the fraction of drug in an oil phase 
to that of an adjacent aqueous phase. Accordingly compounds with relatively high 
partition coefficient are predominantly lipid soluble and consequently have very low 
aqueous solubility. Compounds with very low partition coefficients will have 
difficulty in penetrating membranes resulting poor bioavailability.   
Typical relationship between drug activity and partition Coefficient K, 
generally known as Hansch Correlation and is as follows;   
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d) Pka: 
The relationship between PKa of compound and absorptive environment, 
presenting drug in an unchanged form is adventitious for drug permeation but 
solubility decrease as the drug is in unchanged form  
e) Drug Stability: 
Orally administered drugs can be subject to both acid, base hydrolysis and 
enzymatic degradation. Drugs unstable in GI pH, eg: propantheline can be designed 
for sustained delivery in intestine with limited or no delivery in stomach. On the other 
hand, a drug unstable in intestine, eg: probanthine can be formulated as gastro 
retentive dosage form. 
f) Molecular size and diffusivity: 
 The ability of drug to diffuse through membranes it’s so called diffusivity & 
diffusion coefficient is function of molecular size (or molecular weight).  
 Generally, values of diffusion coefficient for intermediate molecular weight 
drugs, through flexible polymer range from 10-8 to 10-9 cm2 / sec. with values on the 
order of 10-8 being most common for drugs with molecular weight greater than 500, 
the diffusion coefficient  in many polymers frequently are so small that they are 
difficult to quantify i.e. less than 16-12 cm2/sec.  Thus high molecular weight drugs    
display very slow release kinetics in sustained release device using diffusion.  
g) Protein binding: 
 It is well known that many drugs bind to plasma proteins with a concomitant 
influence on the duration of drug action. Since blood proteins are for the most part re-
circulated and not eliminated, drug Protein binding can serve as a depot for drug 
producing a prolonged release profile, especially if a high degree of drug binding 
occurs.  
 Extensive binding to plasma proteins will be evidenced by a long half life of 
elimination for drugs and such drugs generally most require a sustained release 
dosage form. However drugs that exhibit high degree of binding to plasma proteins 
also might bind to bio-polymers in GI tract which could have influence on sustained 
drug delivery  
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B) BIOLOGICAL FACTORS: 
a) Biological Half Life: 
 The usual goal of an oral sustained release product is to maintain therapeutic 
blood levels over an extended period. To action this, drug must enter in the circulation 
of approximately the same rate of which it is eliminated. The elimination rate is 
quantitatively described by half-life (t1/2). Therapeutic compounds with short half 
lives are excellent candidates for sustained release preparations. Since this can reduce 
dosing frequency. In general drugs with half-lives shorter than 3hrs are poor 
candidates of sustained release dosage forms of dose size will increase as well as 
compounds with long half lives, more than 8 hrs are also not used in sustained release 
forms because their effect is already sustained.  
b) Absorption: 
 The rate, extent and uniformity of absorption of a drug are important factors 
when considered its formulation into a sustained release system. As the rate limiting 
step in drug delivery from a sustained-release system is its release from a dosage 
form, rather than absorption. Rapid rate of absorption of drug, relative to its release is 
essential if the system is to be successful. It we assume that transit time of drug  must 
in the absorptive areas of the GI tract is about 8-12 hrs. The maximum half life for 
absorption should be approximately 3-4 hrs. Otherwise device will pass out of 
potential absorption regions before drug release is complete.  
c) Distribution: 
 The distribution of drugs into tissues can be important factor in the overall 
drug elimination kinetics. Since it not only lowers the concentration of circulating 
drug but it also can be rate limiting in its equilibrium with blood and extra vascular 
tissue, consequently apparent volume  of distribution assumes different values 
depending on time course of drug disposition. For design of sustained/ controlled 
release products, one must have information of disposition of drug.  
d) Metabolism: 
 Drugs that are significantly metabolized before absorption, either in lumen or 
the tissue of the intestine, can show decreased bioavailability from slower-releasing 
dosage forms. Most intestinal wall enzymes systems are saturable. As drug is released 
at a slower rate to these regions less total drug is presented to the enzymatic process    
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device a specific period, allowing more complete conversion of the drug to its 
metabolite. 
e) Side effects and safety considerations: 
For some drugs the incidence of side effects in addition to toxicity, is believed 
to be a function of plasma concentration. A controlled- release system can, at times, 
minimize side effects for a particular by controlling it’s plasma concentration and 
using less total drug over the time course of therapy. 
The most widely used measure of the margin of safety of a drug in it’s 
therapeutic index, TI. 
TI = LD50/ED50 
Where, 
LD50  = median lethal dose, 
ED50   = median effective dose. 
For very potent drugs, where therapeutic concentration range is narrow, the 
value of TI is small. In general larger the value of TI the safer the drug. Drugs with 
very small values of TI usually are poor candidates for formulation into controlled 
release products. Primarily because of technological limitations of precise control 
over release rates. A drug is considered relatively safe if it’s TI value exceeds 10. 
 Eg: Drugs with values of TI< 10 are Apobarbital, Phenobarbital, Digitoxin, Digoxin. 
f) Disease state: 
Disease state and circadian rhythm are not drug properties how ever in few 
instances they are equally important as drug properties in considering drug for 
controlled release. A case in point is rheumatoid arthritis, for which aspirin is still a  
drug of choice. Normally aspirin would not be considered to be a likely candidate for 
sustained release because it’s biological half life is 6 hours.   
Initially the ultimate criterion for a sustain release tablet is to achieve a blood 
level and the drug comparable to that of liquid product administered every 4 hrs. To 
this end, prolong release dosage forms are designed to release the drug so as to 
provide a drug level within the therapeutic range for 8 to 12, with a single dose rather 
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than a dose every 4 hrs. No prolonged drug forms have without disadvantages. Since 
gastrointestinal tract is not uniform. If drug release was more slowly then not receive 
proper benefit of response. This is especially true for older people whose 
gastrointestinal tract is less active than that of the younger. Also liberation is slow, 
there is danger of accumulation of the drug after several days resulting in high blood 
levels and a delayed exaggerated response. 
Multi Unit Particulate System offers several advantages such as 
 Improve gastric absorption. 
 Minimize local irritation. 
 Offers high degree of flexibility. 
 Reduces dose dumping. 
 Reduces inter & intra subject variability.
1.4 MULTIPARTICULATES
9, 18, 19, 20
 
  Multiple unit dosage forms are essential where drug-excipients or drug-drug 
physicochemical interaction is possible in a single-unit formulation. They are also 
known to have less variance in transit time through the gastrointestinal tract than 
single-unit dosage forms. They are usually delivered in hard gelatin capsules or made 
into tablets that disintegrate instantly.  
Types of Multiple unit dosage forms comprise 
• Pellets 
• Granules 
• Mini tablets mini depots 
• Micro particles (Microspheres or Microcapsules) 
• Nano particles 
1.5 PELLETS  
Pharmaceutical pellets are agglomerates of fine powder particles or bulk drugs 
and excipients, small, free-flowing, spherical or semi-spherical solid units, size ranges 
from about 0.5mm to 1.5mm (ideal size for oral administration), obtained from 
diverse starting materials utilizing different processing techniques and conditions.  
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Desirable properties of pellets 
Uncoated pellets:   
• Uniform spherical shape and smooth surface 
• Optimum size between 600 and 1000µm 
• Improved flow characteristics 
• High physical strength and integrity 
• Good hardness and low friability 
Coated pellets: 
• High bulk density 
• Ease and superior properties for coating 
• Reproducible packing of beds and columns. 
• Maintain all of the above properties. 
• Contain as much as possible of the active ingredient to keep the size of the 
final dosage form within reasonable limits 
• Have desired drug release characteristics 
 
Figure 5 : (a) Pellets, (b) Perfect pellet, (c) Coated pellet 
Advantages of pellets 
• The smooth surface and the uniform size of the pellets allow uniform coating not 
only for each pellet but also from batch to batch. Coating of pellets can be done 
with different drugs to enable a controlled release rate.  
•  In case of immediate release products, larger surface area of pellets enables better 
distribution. 
•  Chemically incompatible products can be formed into pellets and delivered in a 
single dose by encapsulating them. 
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•  The beads or granules of different thickness of coatings are blended in the desired 
proportions to give the desired effect. 
•  The thickness of the coat on the pellets dictates the rate at which the drug or 
contents are released from the coated particles.  
• By selecting the proper formulation, processing conditions and processing 
equipment, it is possible to attain smooth surfaced and uniform pellets. 
• Improved appearance of the product and the core is pharmaceutically elegant. 
• Pellets can be divided into desired dosage strength without process or formulation 
changes and also allows the combined delivery of two or more bioactive agents 
that may or may not be chemically compatible, at the same site or at different sites 
within the gastrointestinal tract. 
• They offer high degree of flexibility in the design and development of oral dosage 
form like suspension, tablet and capsule. 
• Recently, coated pellets are compressed to rapidly disintegrating tablets. For this 
purpose small pellets with the mean diameters below 0.5 mm are most suitable. 
Such pellets can be produced by direct pelletization methods. 
Disadvantages of pellets 
• The manufacturing of multiple unit dosage forms is more complicated and more 
expensive. 
• The filling into gelatin capsules is difficult to accomplish, especially in the case 
where different subunits are involved.  
 
1.5.1 Theory of pellet formation and growth
19
 
 Nucleation  
 Coalescence 
 Layering
 Abrasion transfer 
Theory of pellet formation can be explained as follows. 
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     Fig 6: (A) Nucleation, (B) coalescence, (C) layering and (D) abrasion transfer 
1.5.2 PELLETIZATION TECHNIQUES: 
Pelletization is an agglomeration process that converts fine powders or 
granules of bulk drugs and excipients into small, free-flowing, spherical or semi-
spherical units, referred to as pellets. The type of coating technique strongly affects 
the film microstructure and thus affects the release mechanism and rate from pellets 
coated with polymer blends. There are several manufacturing techniques for 
production of spherical pellets. 
The techniques involved are 
       1. Agitation 
       2. Compaction 
       3. Layering 
       4. Globulation 
 
Fig 7: Different Pelletization Techniques 
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1.5.2.1. AGITATION: 
 a) Balling:   
           Finely divided particles are converted upon the addition of appropriate 
quantities of liquid, to spherical particles by a continuous rolling or tumbling motion. 
Pans, discs, drums, or mixers may be used to produce pellets by the balling.            
1.5.2.2. COMPACTION: 
a) Compression:  
           Mixtures or blends of active ingredients and excipients are compacted under 
pressure to generate pellets of defined shape and size.  
b) Extrusion – Spheronization:  
           It is a multistep process invented by Nakahara, in 1964, involves dry mixing of 
the active compound with excipients, granulation of wetted mass, extrusion of the 
mass, transfer of the mass to spheronizer to produce spherical shape, drying of the 
wetted mass in a dryer, and at the end screening to obtain required particle size. 
 
Figure 8: Principle of Extrusion – Spheronization process 
1.5.2.3) LAYERING: 
In this process, drug is layered onto seed materials (generally, a coarse 
material or nonpareil) in powder, solution or suspension form and leads to 
heterogeneous pellets, which consist of an inner core region and an outer shell region 
of a different composition. This process is classified into three categories namely  
a. Direct pelletization, 
b. Powder layering, 
c. Solution or suspension layering 
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a) Direct pelletization 
A process that leads to formation of homogeneous pellets which have 
microscopically uniform structure and no core can be detected. Direct pelletization is 
mainly performed in high shear mixers and fluidized bed equipment 
 
 
 
 
 
 
                                    Figure 9: Principle of direct pelletization process 
 b) Powder Layering 
Powder layering involves the deposition of successive layers of dry powder of 
drug or excipients or both, on preformed nuclei or cores with the help of a binding 
liquid.  
 
Figure 10: Principle of Powder layering process 
Equipment used is tangential spray/centrifugal/rotary fluidized bed granulator. 
This technology is applied to produce sustained release Cyclobenzaprine 
Hydrochloride multiple unit pellets for improving the drug release in acidic media, 
due to the enhancement of the polymer film formation on the surface of the pellet. 
Some of the disadvantages are: 
• Low amount of drug loading which is not suitable for high-dose drugs 
• Final composition of pellets can vary if spray loss occurs. 
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c) Solution/Suspension layering: 
In the case of Solution/Suspension layering, growth of pellets involve 
deposition of successive layers of solution and/or suspension of drug substance and 
binders on existing nuclei, which may be inert seed, crystal or granule. The drug 
particles are dissolved or suspended in the binding liquid, with or without the binder. 
Droplets of the binding liquid spread on the surface of the nuclei.  
 
Figure 11:  Principle of Solution/Suspension layering process
During drying, liquid evaporates and the dissolved substances crystallize out 
and capillary forces which are formed draw the particles towards each other and 
towards the inert seed, forming solid bridges. In suspension layering, particles have 
low solubility and are bonded by solid bridges formed from the hardening binder i.e., 
that higher concentration of binder might be necessary.          
 Suspension layering is usually used when the desired drug loading of the 
pellets is low because production of pellets from low solids content formulation is not 
economically feasible. 
          The most common configuration used is Wurster bottom spray coater. 
1.5.2.4. GLOBULATION: 
Globulation or droplet includes spray drying and spray congealing.  
a) Spray drying: Drug entities in solution or in suspension form are sprayed, with or 
without excipients, into a hot air stream to generate dry and highly spherical particles. 
It is generally employed to improve the dissolution rates and hence, bioavailability of 
poorly soluble drugs.  
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b) Spray congealing: A process in which a drug is allowed to melt, disperse, or 
dissolve in hot melts of gums, waxes, fatty acids, etc., and is sprayed into an air 
chamber where the temperature is below the melting points of the formulation 
components, to provide spherical congealed pellets under appropriate processing 
conditions.   
1.5.3 COATING OF PELLETS: 
         The application of coating is usually based on one or more of the following: 
 To mask the taste, odor or color of the drug. 
 To provide physical and chemical protection to the drug. 
 To control the release of the drug. 
 To protect the drug from the gastric environment of the stomach 
with an acid resistant coating. 
 To incorporate another drug or formula adjuvant in the coating 
to avoid chemical incompatibility or to provide sequential drug 
release. 
 To provide pharmaceutical elegance by use of special color. 
1.5.3.1 TYPES OF COATING: 
a. Sugar coating 
b. Film coating 
c. Enteric coating 
d. Extended release coating. 
 Sustained release coating is used in the present formulation. Commonly used 
sustained release polymers are 
  Ethyl cellulose, cellulose acetate, polyvinyl acetate, neutral copolymers based 
on ethyl acrylate & methyl acrylate, eudragit NE, RS or RS 30D, RL or RL 30D. 
1.5.4. COATING EQUIPMENTS: 
Most of the coating processes use one of three general types of equipments. 
1. The conventional Coating pan 
2. The Perforated Coating pan 
3. The Fluidized bed coater 
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1.5.4.1. Conventional Coating Pan: 
 In this technique the granules or sugar spheres are placed in the coating pan 
and the coating solution is sprayed on the granules by atomizer with pressure.                         
 
Fig 12 : Conventional Coating Pan 
 1.5.4.2. Perforated coating pan:          
        Neocota is an automatic coating system for tablets and pellets. Neocota is a 
completely updated automatic coating system having a batch capacity of 500 g to 1kg. 
This model efficiently carries out the following operations: Aqueous film coating of 
tablets/pellets; Non-aqueous organic solvent Based film coating of tablets/pellets; and 
Enteric Film coating of tablets/pellets. The basic units of the system are: Coating pan 
has perforations along its cylindrical portion. It is driven by a variable speed drive 
with a flame-proof motor.  
 
 
 
 
 
 
Figure 13: NEOCOTA(Perforated pan) 
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Supply of hot air and exhaust of drying air are arranged to facilitate the 
coating system through stainless steel plenums positioned on both sides of the 
perforated coating pan. The pan is enclosed in a cylindrical air tight housing provided 
with a suitable door and frontglasswindow. This housing of pan with drive is a 
stainless steel Cabinet accommodating the gearbox, AC variable drive, power panel, 
hot air unit, ex-haust unit and an air fitter. Fig showing Neocota is an automatic 
coating system for tablets having a capacity of 500g to1kg. Aqueous film coating and 
non aqueous film coating is carried out in Neocota. 
1.5.4.3. The Fluidized bed coater or Fluidized Bed Processor (FBP)
20
 
The Fluid Bed Technology offers a very efficient coating technique. The 
major advantage of the Fluid Bed Systems is that it is as per GMP standards it is a 
closed system. The second advantage of the Fluid Bed Systems is that not only 
coating but granulation and pellet formation is also possible in the same machine. 
There is considerable diversity in methods of using fluidized bed technology. For e.g. 
liquids can be applied to fluidized particles in a variety of ways, including top, bottom 
and tangential spraying.  
  Production of homogenous pellets is usually carried out in extruder              
spheronizer, high-shear mixer and rotary fluidized bed, while the production of 
heterogeneous pellets and particle coating is carried out in top spraying or different 
types of bottom spraying fluidized bed equipment. 
  A fluidized bed system is a unique process for uniform, continuous and 
coating of granulates, pellets and powders. Aqueous or organic coatings can be 
applied. Coating and drying takes place in one machine.  
 Principle of Operation: 
 In fluid bed processor, particles are fluidized and the coating fluid is sprayed 
on and dried. Small droplets and a low viscosity of the spray medium ensure an even 
product coating. 
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                                           Figure 14: Fluidized Bed Processor 
Advantages of Fluidized Bed Processor: 
• All-in-one process from demanding powder coating to simple drying.  
• Unique technology that combines outstanding spray behavior with optimum 
media delivery and easy cleaning. 
• Simple handling for both horizontal and vertical product flow can be realized with 
all sizes.  
• The unique ABC-technology (Anti-Bearding-Cap) allows spraying without 
bearding. The perfect supplement to the ABC-technology is the unique Nano-
coating to the nozzle which prevents the deposit of coating material on the nozzle 
cap.  
 No process downtime due to cleaning of the nozzle  
 No blocked liquid inserts  
 No interference of spray pattern  
• Process advantages are uniform, continuous product coating. Aqueous or organic 
coatings can be applied. Coating and drying take place in one machine.  
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1.5.4.3.1. Types of Fluid Bed Systems
20
 
a) Top Spray (Granulator) 
b) Bottom Spray (Wurster Coating)  
c) Tangential Spray (Rotor Pellet Coating) 
a) Granulator/Top-spray process  is preferred when a taste masking coating is 
being applied. Additionally it is suitable for the application of hot melt coating. 
b) Wurster/Bottom spray process  is preferred for the application of modified-
release coating to a wide variety of multi-particulates; also suitable for drug layering 
when the drug dose is in the low to medium rage.  
  In this process, a complete sealing of the surface can be achieved with a low 
usage of coating substance.  When the hot air flows through the bottom screen of 
container and coating column, it will generate the siphonage principle.  Convection is 
created through the strong force from bottom toward top.  The granules will then fall 
down and will be sucked into the coating column again, while the bottom spray gun 
will spray towards top to achieve coating purpose.  As the particles continue traveling 
upwards, they dry and fall outside the Wurster tube back towards the base plate. 
c) Rotor/ Tangential spray process  is suitable for the application of modified-
release film coating to a wide range of multi-particulate products. It is ideal for drug 
layering when the dose is medium to high. It is also useful as a spheronizing process 
or producing spheres.      
 
Fig 15 :(a) Principle of Bottom spray batch fluid coating.  (b) Principle of Top- 
spray batch fluid coating.     (c) Principle of Tangential spray batch fluid coating 
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1.5.5. Variables in FBP: 
a. Formulation-related variables 
b. Equipment-related variables 
c. Process-related variables 
Table No.2: Formulation Related Variables: 
   Variable                                       Effect 
a) Primary Materials 
 
Low particle density, a narrow particle size range, crystalline 
or amorphous nature, and wettability, a particle shape that 
approaches spherical, a lack of particle cohesiveness, and a 
lack of stickiness during the processing are effective. 
b) Binder(type, 
binder concentration 
and content) 
Low friability, uniform flow, low bulk density, porosity, and 
size distribution are effective. 
c) Solvent for Binder 
 
The selection of solvent, such as aqueous or organic, depends 
on the solubility of the binder and the compatibility of 
product being granulated.   
 
Table No.3: Equipment-Related Variables: 
Variable Effect 
a) Design 
 
Difficulty in scaling up from the laboratory units in a linear 
scale due to different suppliers. 
b) Air Distributor 
Plate 
Identified by their percentage of open area. 3-40% of open 
area normally available. 
Small open area: large pressure drop, uniform fluidization. 
c) Pressure Drop(_P) 
 
A blower with an appropriate _P will fluidize the process 
material adequately.    
d) Shaker and Blow-
Back Cycle 
Mechanism 
Bag filters with a blow-back or use of stainless steel filter 
bags in which air under pressure is pulsed through the filters. 
e) Other equipment 
factors 
 
Granulator bowl geometry, conical shape of the container and 
expansion chamber is preferred in which the ratio of cross-
sectional diameter of the distributor plate to the top of the 
vessel is 1:2. 
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Table No.4: Process related variables: 
Process parameter Effect 
a) Inlet air 
temperature 
Higher: finer granules. 
Lower: larger, stronger granules. 
b) Humidity Increase in humidity: larger granule size, longer drying times. 
c) Fluidizing airflow 
 
Proper airflow should fluidize the bed without clogging the 
filters. Higher airflow will cause attrition and rapid 
evaporation, generating smaller granules and fines. 
d) Nozzle and nozzle 
height 
A binary nozzle produces finest droplets and is preferred. 
Optimum nozzle height should cover the bed surface. 
Too close to the bed: will wet the bed faster, producing larger 
granules. Too high position: creates finer granules, and 
increase granulation time. 
e) Atomization air 
volume and pressure 
Liquid is atomized by the compressed air. This mass/liquid 
ratio must be kept constant to control the droplet size, and 
granule size. Higher liquid flow rate will produce larger 
granules and the reverse will produce smaller granules. At a 
given pressure, an increase in orifice size will increase 
droplet size and liquid throughput. 
f) Binder spray rate 
 
Droplet size is affected by liquid flow rate, binder viscosity, 
and atomizing air pressure and volume. The finer the droplet, 
the smaller the resulting average granules. 
g) Rotor Speed Higher rotation rates resulted in excessive friability of the 
cores and loss of the coating powder. 
h)  Spray rate  Lower spray: longer processing time resulting in a lower 
porosity of the pellets. Higher spray: higher water content, 
shorter processing time and larger pellets, shorter time for 
liquid to evaporate, broader size distribution. 
i) Moisture content 
 
There is sensitive relation between moisture content and 
particle size, and moisture sensitivity depends strongly on the 
formulation, especially the fraction of pelletization aid. 
 
 1.5.6. Excipients for pellets: 
Formulation aids or excipients are added to pharmaceutical dosage forms 
mainly to produce satisfactory delivery of the drug to the intended site, to impart 
favorable characteristics to the dosage form. The excipients used in the pellet dosage 
forms are typically the same as those used in tablet or capsule formulations.              
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Table No.5: Examples of commonly used excipients 
Filler MCC, starch, sucrose, lactose, mannitol 
Binder Gelatin, HPC, HPMC, MC, PVP, 
sucrose, starch 
Lubricant Calcium stearate, glycerin, PEG, Mg. 
stearate 
Separating agent Kaolin, talc, silicon dioxide 
Disintegrant Alginates, croscarmellose sodium 
PH adjuster Citrate, phosphate, meglumine 
Surfactant Polysorbate, Sodium lauryl sulphate 
Glidant Talc, starch, Magnesium stearate 
Release modifier Ethyl cellulose, carnauba wax, shellac 
 
1.6. CAPSULES 
21, 22
               
Capsules are solid dosage forms in which the drug or a mixture of drugs is 
enclosed in hard or soft gelatin capsules. These shells made up of gelatin and this can 
be intended for oral administration. 
               These are available in various sizes, shapes and capacity. 
1.6.1. TYPES OF CAPSULES  
                  a) Hard gelatin capsules  
                  b) Soft gelatin capsules  
Both of these classes of capsules are made from aqueous solutions of gelling 
agents like, i) Animal protein mainly gelatin, ii) Plant polysaccharides or other 
derivatives like carragenans and modified forms of starch and cellulose.  
 Other ingredients can be added to the gelling agent solution like plasticizers 
such as glycerin and/or sorbitol to decrease the capsule's hardness, coloring agents, 
preservatives, disintegrants, lubricants and surface treatment.             
a) Hard gelatin capsules  
Which are normally used for dry, powdered ingredients or miniature pellets 
(also called spheroids that are made by the process of Extrusion and Spheronization) 
or tablets. These sizes are designed by in numbers. 
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  Table No.6: Capsules sizes and their fill weights 
 
S.No 
 
Size of capsules 
 
Volume in ml 
 
Fill weight in mg 
   1          000        1.37 615-1370 
2 00 0.95 430-950 
3 0 0.68 305-680 
4 1 0.50 225-500 
5 2 0.37 165-370 
6 3 0.30 135-300 
7 4 0.21 95-210 
8 5 0.13 60-130 
b) Soft gelatin capsules 
          Which are primarily used for oils and for active ingredients that are dissolved or 
suspended in oil.These are classified depending upon the sizes and capacities. 
          The number represents capacities in minims 
1) Round-1,2,3,4,,5,6,7,8,9,28,40,40T,80T and 90T. 
2) val-1,2,3,4,,5,6, 7..5,10,12,16,20,40,60,80,85 and 110. 
3) Obolong-3,4,5,6,8,9.5,11,14,16,20,90 and 360. 
4) Tube-5,6,8,17.5,30A,30B,35,45,55,65,90,160,250,320 and 480. 
5) Misc-6, 17, 30, 35, 60 and 80. 
1.6.2. Capsules Standards and limits 
a) Description 
          It should comply with specifications of product. 
b) Content of active ingredients 
          Limit: 90 to110% of label claim or as per In house limit. 
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 c) Uniformity of weight 
Table No.7. 
Average weight of 
capsules content 
Percentage 
deviations allowed 
less than 300mg 10% 
300mg or more 7.5% 
  
d) Disintegration test 
 i) Hard gelatin capsules 
Disintegration time shall not be more than 30 min. 
 ii) Soft gelatin capsules  
Disintegration time shall not be more than 60 min. 
 
Table No.8: Standard length & locked length for hard gelatin capsules in mm 
 
Size Cap Body Locked length 
000 12.80-12.95 22.10-22.20 26.4 
00 11.74-11.86 20.12-20.25 23.3 
0 10.68-11.68 18.22-19.22 21.7 
1 9.51-10.51 16.22-17.22 19.4 
2 8.67-9.67 14.84-15.84 18.0 
3 7.73-8.73 12.98-13.98 15.9 
4 6.97-7.97 11.84-12.84 11.1 
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1.7 SKELETAL MUSCLE RELAXANTS 
1.7.1. HISTORY 
23
 
The earliest known use of muscle relaxant drugs dates back to the 16th 
century, when European explorers encountered natives of the Amazon Basin in South 
America using poison-tipped arrows that produced death by skeletal muscle paralysis. 
This poison, known today as curare, led to some of the earliest scientific studies in 
pharmacology. Its active ingredient, tubocurarine, as well as many synthetic 
derivatives, played a significant role in scientific experiments to determine the 
function of acetylcholine in neuromuscular transmission. By 1943, neuromuscular 
blocking drugs became established as muscle relaxants in the practice of anesthesia 
and surgery. 
  The U.S. Food and Drug Administration (FDA) approved the use of 
Cyclobenzaprinehydrochloride was approved on August 26, 1977 
1.7.2. Muscle spasm:                          
  Many diseases of the brain and spinal cord produce an increase in muscle tone 
(is sustained partial muscle contraction), which can be painful and disabling. 
Spasticity resulting from birth injury or cerebral vascular disease, and the paralysis 
produced by spinal cord lesions are examples. Local injury or inflammation, as in 
arthritis, can have the same effect, and chronic back pain is also often associated with 
local muscle spasm. 
1.7.3. Skeletal muscle relaxants 
24, 25 
  A muscle relaxant is a drug which affects skeletal muscle function and 
decreases the muscle tone and / or cause paralysis. It may be used to alleviate 
symptoms such as muscle spasms, pain, and hyperreflexia. The term "muscle 
relaxant" is used to refer to two major therapeutic groups. 
  1. Neuromuscular blockers (or) peripherally acting muscle relaxants 
  2. Spasmolytics (or) centrally acting muscle relaxants 
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                Neuromuscular blockers act by interfering with transmission at the 
neuromuscular end plate and have no CNS activity. They are often used during 
surgical procedures and in intensive care and emergency medicine to cause paralysis. 
Spasmolytics, also known as "centrally-acting" muscle relaxants, are used to alleviate 
musculoskeletal pain and spasms and to reduce spasticity in a variety of neurological 
conditions. While both neuromuscular blockers and spasmolytics are often grouped 
together as muscle relaxant. The term is commonly used to refer to spasmolytics only.                
1.7.3.1. CLASSIFICATION: 
I.) PERIPHERALLY ACTING MUSCLE RELAXANTS: 
     1. NEUROMUSCULAR BLOCKING AGENTS: 
       A. Non depolarizing (competitive) blockers 
        1. Long acting : 
  d-tubocurarine, 
  pancuronium, 
  pipecuronium. 
 2. Intermediate acting: 
  Vecuronium, 
Atracurium, 
Cisatracurium, 
Rapacuronium. 
  3. short acting:  
  Mivacurium. 
       B. Depolarizing blockers: 
    Succinyl choline, 
    Decamethonium. 
      2. DIRECTLY ACTING AGENTS: 
       Dantrolene sodium, 
        Quinine. 
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II.) CENTRALLY ACTING MUSCLE RELAXANTS: 
      I. mephenesin group   
Mephenesin, 
Methocarbamol, 
Chlorzoxazone, 
Chlormezanone. 
      II. Benzodiazepines 
Diazepam, 
Clonazepam, 
Clobazam. 
Cyclobenzaprine. 
      III. GABA Derivative 
  Baclofen 
      IV. Central 2 agonist 
  tizanidine                                      
I.) PERIPHERALLY ACTING SKELETAL MUSCLE RELAXANTS: 
26
 
a) Neuromuscular blocking agents: 
  These drugs block cholinergic transmission between motor nerve endings and 
the nicotinic receptors on the neuromuscular end plate of the skeletal muscle. These 
Neuro muscular blockers are structural analogs of acetylcholine, and either as 
antagonist (non depolarizing type) or agonists (depolarizing type) at the receptors end 
plate of the neuromuscular junction. 
  Neuro muscular blockers are clinically useful during surgery for produce 
complete muscle relaxation, without having to employ higher anaesthetic doses to 
achieve comparable muscle relaxation. 
b) Directly acting agents: 
 The drug like Dantrolene which acts directly on muscles by interfering with the 
release of calcium from the sarcoplasmic reticulum, and Baclofen, which acts at 
GABA receptors in the central nervous system. 
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II.) CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS 
25
 
  These are drugs which reduce skeletal muscle tone by a selective action in the 
cerebrospinal axis, without altering consciousness. They selectively depress spinal 
and supraspinal post synaptic reflexes involved in the regulation of muscle tone 
without significantly affecting monosynaptically mediated stretch reflex. Poly 
synaptic pathways in the ascending reticular formation which are in the maintenance 
of wakefulness are also depressed, through to a lesser extent. All centrally acting 
muscle relaxants do have some sedative property. They have no effect on 
neuromuscular transmission and on muscle fibres, but reduce deliberate rigidity, 
upper motor neurone spasticity and hyper reflexia. 
 
                                       
                      Fig.16 : Mechanism of action of centrally acting muscle relaxants. 
A view of the spinal cord and skeletal muscle showing the action of various 
muscle relaxants. Black lines ending in arrow heads represent chemicals or actions 
that enhance the target of the lines. Blue lines ending in squares represent chemicals 
or actions that inhibition the target of the line. 
  The generation of the neuronal signals in motor neurons that cause muscle 
contractions are dependent on the balance of synaptic excitation and inhibition that 
the motor neuron receives. Spasmolytic agents generally work by either enhancing the 
level of inhibition, or reducing the level of excitation. Inhibition is enhanced by 
mimicking or enhancing the actions of endogenous inhibitory substances, such as 
GABA.                  
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2. Literature Review 
2.1. Literature Review of Drug Delivery 
Gangane PS et al.,(2008)
27 reported the preparation of cinnarazine pellets by 
powder-layering technique, using Cinnarizine as active ingredient and Eudragit RS-
100, Eudragit RL-100, Ethyl cellulose as coating agent, with propylene glycol as 
plasticizers and PVPK-30 as binder. Pellets coated with 10% Eudragit RS-100 
showed promising results releasing more than 95% of drug up to 12 hours. This study 
concluded that the powder layering technique can be used for designing sustained 
release drug delivery systems providing drug release over a period of 12 hours. 
Crilles C. Larsen et al., (2003)
28 reported the parameters with effect on 
maximum spray rate maximum relative outlet air humidity when coating pellets in a 
fluidized bed. The tested variables include type of water based modified release film 
coating (aqua coat ECD) coating principle (top spray, bottom spray) , inlet air 
humidity and type of pellets (sugar spheres, microcrystalline cellulose). The 
maximum spray rate was not influenced by the coating principles. 
Simon Ensslin et al., (2008)
29
 studied internal structure and drug release 
mechanism of modified release pellets coated with blends of poly vinyl acetate 
(PVAc) and poly vinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG). The 
highly soluble drug Chlorpheniramine maleate (CPM) was used as a model 
compound. A faster water influx into PVAc/PVA-PEG film coated pellets did not 
result in a fast drug release. Despite a fast drug solubilization within the pellets, drug 
release was initiated after 2 hrs, suggesting a one way stream of water during the 
observed lag-time. 
Sreekhar cheboyina et al., (2008)
30 reported a novel freeze pellatization 
technique for the preparation of wax based sustained release matrix pellets for water-
soluble drugs. The drug release significantly depended on the wax type used and the 
aqueous drug solubility. The drug release decreased as the hydrophobicity of wax 
increased. In glyceryl monostearate (GMS) pellets, drug release rate decreased as the 
loading of theophylline increased. On the contrary, the release rate increased as the 
drug loading of diltiazem HCl increased in precirol pellets. 
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Nantharat Pearnchob et al., (2003)
 31studied the powder layering technique 
with ethyl cellulose powder to achieve extended release. The film forming ability of 
ethyl cellulose powder and the effect of formulation factors (plasticizer type and 
concentration) and curing conditions (curing temperature and time) were investigated. 
The coating formulation was divided into two components consisting of a powder 
mixture (polymer plus talc) and a mixture of liquid materials (plasticizer plus binder 
solution), Propranolol hydrochloride was used as a model drug, Despite the high glass 
transition temperature of ethyl cellulose (133.40C), micronized ethyl cellulose powder 
can be used for dry powder coating by adjusting the coating temperature, amount and 
type of plasticizer applied, and curing conditions. 40% plasticizer and a curing step 
(800C, 24 h) were required to achieve complete coalescence of the polymer particles 
and extended drug release of coated pellets. Although ethyl cellulose-coated pellets 
had an uneven surface, extended drug release could be obtained with coating level of 
15%.  
Shajahan Abdul et al., (2010)
32 studied a flexible technology, MUPS 
(multiple unit particulate system) for modified-release drugs. Oral modified –release 
multiple- unit dosage forms have always been over effective therapeutic alternative to 
conventional or immediate release single-unit dosage forms. The multi particulates 
are usually formulated into single unit dosage forms such as filling them into hard 
gelatin capsules or compressing them into tablets. These MUPS are expected to 
disintegrate rapidly into individual pellets and provide drug release profile similar to 
that obtained from uncoated pellets. 
 Caroline De sire e Kablitz et al.,(2008)33 reported the dry coating process is 
an emerging coating technology using neither organic solvents nor water. In contrast 
to liquid-borne coatings, coating material application and film formation are divided 
into two phases, the coating phase where the powdery coating material is applied 
together with the liquid plasticizer, and the curing phase. In this study the coating 
phase was characterized with respect to the forces acting between the polymer 
particles during material application. HPMC was used as enteric resistant polymer, 
triethyl citrate (TEC), Myvacet (di acetylated mono glyceride) and a mixture of both 
as liquid additives. Inter particle forces were found to be similar when using TEC or a 
mixture of TEC and Myvacet_. In contrast, inter particle forces were higher when 
using solely Myvacet. This is attributed to the fact that Myvacet does not penetrate 
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into the polymer without TEC which is acting as a penetration enhancer. The highest 
inter particle force determined by AFM is in accordance to the highest coating 
efficiency which has been found for the corresponding coating formulation containing 
HPMC AS and Myvacet.  
Kumar vikas et al., (2011)
34
 reported the pelletization technique with the 
advent of controlled release technology that the full impact of the inherent advantages 
of pellets over single unit dosage forms have been realized, not only has focused on 
the refining and optimizing pelletization techniques, but also focused on the novel 
approaches and procedures for manufacturing of pellets. The present review outlines 
the manufacturing and evaluation of pellets. There are various types of pellatization 
techniques like spheronization and extrusion, pelletization by powder layering, 
pelletization by solution layering &direct pelletization. The techniques namely 
extrusion and spheronization, hot melt extrusion cryo pellatization have been 
discussed along with parameters affecting pellatization. 
Balasubramaniam J et al.,
35
 reported the multi particulate pellets containing 
esomeprazole magnesium have been prepared using an extrusion spheronization 
process, employing povidone and crospovidone as non-traditional processing aids. 
Attempts have been made to prepare pellets of various sizes and ultimately investigate 
the levels of enteric coating that need to be applied in order to achieve a suitable 
delayed-release dissolution profile. While acceptable pellets, displaying appropriate 
drug delayed-release characteristics have been achieved, it is evident from this initial 
study that further formulation and processing refinements, with respect to the 
formation of the initial pellets, need to be made in order to create pellets with optimal 
sphericity characteristics and narrower particle size distributions. 
 Claudio Nastruzzi et al., (2000) studied the powder layering 
technique and also influence of formulation and process parameters on pellet 
production by pan technique. Here, in this study inert cores were intermittently treated 
with micronized drug powder and adhesive solution, which led to the formation of 
multiple layers of drug particles around and inert core resulting in the production of 
pellets that can be further coated by different polymers to obtain modified release 
formulations. Here in this study they used enteric polymer like acrylic polymer 
Eudragit L 30D and model drug as ibuprofen.  
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Singh S K et al., (2009)
36
 studied the development of delayed release micro 
pellet dosage form for Lansoprazole which is a benzimidazole anti ulcer agent. The 
approach of the present study was to make a comparative evaluation of polymers and 
excipients and to assess the effect of physicochemical nature of the active ingredients 
on the drug release profile. The prototype formulation of micro pellets were prepared 
using the fluid bed coater (FBC) with the air pressure 2.0 bar and the spray rate 10-
15ml/min. Inlet temperature 60°C and bed temperature of 40°C is reliable for solution 
flow rate 10-15ml/min. Concerning results of prototype preparation of Lansoprazole 
the micro pellets were prepared using HPMC E5 polymer as release retardant in three 
different concentration i.e. 40%, 50%, 60% with three different concentration 8%, 
10%, 12% of NaOH and Acrycoat L30D solution was used for enteric coating. 
Formulated micro pellets showed delayed in vitro dissolution behavior, probably due 
to optimized concentration of polymer.  
 Nicolas Follonier et al., (1995)37 studied the various ways of modulating the 
release of drug from hot melt extruded sustained release pellets prepared using 
polymeric materials. Diltiazem hydrochloride was used as a highly dosed, freely 
soluble model drug. Pellets obtained with this technique can be filled into hard gelatin 
capsules. To optimize the release profile of the drug the influence of different 
parameters, such as polymer type, addition of pore forming additives and hydrophilic 
polymers or size of pellets was studied. Swelling agents were included into the pellets 
, which reduces the burst release of drug. 
Anette Pauli-Bruns et.al., (2010)
38 studied one-step preparation of sustained 
release matrix pellets, using a melting procedure in a fluidized bed apparatus, and 
tested in a full factorial design of experiments, using microcrystalline wax as 
lipophilic binder, theophylline as a model drug and talc as additional matrix forming 
agent. The three influence parameters were (A) size of binder particles, (B) fraction of 
theophylline in solid particles and (C) fraction of microcrystalline cellulose wax in 
formulation. 
 Rama Rao Nadendla et al.,(2011)39 reported the design, characterization and 
in vitro evaluation of sustained release pellets of metoprolol succinate to reduce the 
dosing frequency employing pan coating technology. Initially metoprolol pellets were 
prepared by solution layering technology over non-pareil seeds employing pan 
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coating technology. Later, to sustain the release of drug over a period 20 hrs, 
secondary coating was given over the drug layered pellets using ethyl cellulose/ ethyl 
cellulose-hydroxy propyl cellulose were used to prepare different formulations. The in 
vitro dissolution studies revealed that the release rate is inversely proportional to 
percent of coating thickness. The mechanism of drug release follows Higuchi 
diffusion model. 
2.2. Literature review of polymers 
F. Siepmann et al., (2009)
40 studied adjusting desired drug release patterns 
from ethyl cellulose coated dosage forms. Theophylline was used as model drug. 
Most important from a practical point of view, a broad spectrum of pH-independent 
drug release rates can easily be obtained from drug loaded pellets by simply varying 
the PVA-PEG graft copolymer content. An appropriate curing step after coating is 
required, but interestingly the investigated curing conditions (differing in time and 
relative humidity) resulted in very similar drug release patterns, indicating that stable 
film structures are likely to be achieved. 
M.F. Saettone et al., (1995)
41 studied the effect of different polymer 
plasticizer combinations on ‘in-vitro’ release of theophylline from coated pellets. This 
investigation evaluated the influence of different plasticizer/polymer combinations on 
theophylline (TH) release from pellets coated with latex aqueous dispersions of ethyl 
cellulose (EC) or acrylic polymers (ACR). For both types of coating, the drug release 
rate decreased with increasing plasticizer content. A correlation was found between 
the permeability coefficients (Pwv) to water vapour of free films, having the same 
composition as those used for coating, and drug release. 
 J.B. Dressman et al., (1995)42 reported the aqueous latex dispersions of ethyl 
cellulose are often used to form controlled release coatings on pharmaceutical dosage 
forms.  These products exhibit pH dependent release characteristics, with release rates 
typically being slow in water and dilute acid solutions and faster in solutions buffered 
to pH values near neutral. The source of this pH dependant release is not obvious, 
since the principle mechanism of release is by osmotic pumping, the coating polymer 
is neutral and the effect is seen even with drugs that do not ionize within the pH range 
. In this research used phenyl propanolamine HCl pellets over coated with ethyl 
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cellulose to investigate the source of pH dependency of release. pH dependency of 
release was observed in all batches plasticized with dibutyl sebecate, tri ethyl citrate 
was used as the plasticizer, release was virtually independent of pH. 
Anand kumar M et al., (2011)
43 reported the development  and optimization 
of  oral extended release formulation for tamsulosin hydrochloride using a 
combination of ethyl cellulose N-50 and Eudragit L-100 as a coating material. 
Initially trials were done to optimize the drug loading on to sugar pellets for its 
uniformity of size and Assay, varying the concentration of HPMC E-5 as binder, 
Aerosil as lubricant and sodium starch glycollate as disintegrant. The optimal coating 
formulation was achieved with Eudragit L-100  9% of the weight of the drug loaded 
pellets and ethyl cellulose N-50 with 25% of the Eudragit L-100 content. The drug 
release from the optimized pellets was compared with the Innovator product ,It 
showed the similarity factor (F2) of 76.43. 
Fatemeh Sadeghi et al., (2003)
44 studied the release of metoclopramide 
hydrochloride (a water-soluble cationic drug) and diclofenac sodium (a sparingly 
soluble anionic drug) from pellets coated with ethyl cellulose from aqueous ethyl 
cellulose dispersion (Surelease) at different coating loads was investigated. The 
release rates of each drug decreased as the coating load of Surelease increased. 
However, despite its lower water solubility, diclofenac sodium was released slightly 
faster than metoclopramide hydrochloride at equivalent coating loads. Differences 
between the release behaviour of the two drugs were probably due to an interaction 
between  metoclopramide and the ammonium oleate present in the Surelease. The 
slower release of metoclopramide hydrochloride may be due to formation of a poorly 
soluble complex of the drug and the ammonium oleate. This complex, because of its 
large molecular size, may diffuse more slowly through the film, causing a reduction in 
the release rate of metoclopramide hydrochloride.  
Cristoph Schmidt et al., (2001)
45 reported the novel alternative to the 
incorporation into hard gelatin capsules or tablets, extended-release (Aquacoat- or 
Eudragit RS-coated) or enteric (Eudragit L-coated) pellets were embedded into 
congealed tablet-shaped PEG-plugs of different molecular weights, which rapidly 
released the pellets upon contact with aqueous fluids. The lower-molecular- weight 
PEGs (600 and 1000) were not suitable carrier materials: they dissolved the coatings 
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or significantly increased their permeability. The release characteristics of the original 
pellets were maintained after embedding the pellets into the higher-molecular-weight 
PEGs 4000 or 10,000. Aquacoat-coated pellets embedded in PEG 4000 exhibited a 
decreased drug release because of curing effects. Eudragit RS-coated pellets, stored at 
room temperature or above, showed an increased release. 
Johan Hjartstam et al., (1998)
46 reported the swelling behaviour of 
membrane-coated drug pellets . A coating membrane containing ethyl cellulose (EC) 
and hydroxy propyl methylcellulose (HPMC) in the range of 10–24% was used. By 
measuring the release rate of a drug during swelling experiments, it is possible to 
obtain an insight into the release mechanisms that are involved. The results revealed 
that the swelling of the membrane coat increased as the amount of HPMC increased. 
The expansion of the pellets continued until the release of the drug began, and  also 
evaluated the swelling of pure EC:HPMC, where no change in volume occurred. It is 
believed that the swelling of the pellet coat is a result of water imbibition due to 
osmotic pressure. 
Bernhard C Lippold et al., (1999)
47
 reported the release mechanisms of 
theophylline pellets coated with an aqueous ethyl cellulose (EC) dispersion containing 
plasticizers and hydroxy propyl methylcellulose (HPMC) as a water soluble pore 
former. Three different drug release mechanisms from coated pellets can be 
determined as a function of the water solubility of the plasticizers and the ionic 
strength of the release medium. Coated pellets with the addition of more hydrophilic 
plasticizers such as tri ethyl citrate (TEC) or diethyl phthalate (DEP) show an 
approximate zero-order-release rate. In contrast, two-phase release profiles can be 
observed from pellets coated with dispersions containing hardly soluble plasticizers 
such as di butyl phthalate (DBP) or di butyl sebacate (DBS).The drug diffuses through 
a hydrated swollen membrane containing EC, HPMC and insoluble plasticizer. The 
release mechanisms depend on the glass transition temperature of the ethyl cellulose 
and migration of the plasticizers and the pore former.  
2.3. Literature review of drug 
 Jamunadhevi V. et al., (2011)
48
 reported the bilayer tablet of 
Cyclobenzaprine hydrochloride (CBH) and diclofenac potassium (DP) for the 
effective  treatment of severe pain due to inflammation and muscle spasm. DP was 
formulated as immediate release layer and was prepared by wet granulation method 
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using purified water mixed with extra granular excipients. CBH was formulated as 
exteneded release layer using hydrophilic matrix (HPMC K100). The dissolution 
study of extended release layer showed that an increasing amount of HPMC results in 
reduced Cyclobenzaprine release.   
 Arnold J Weil, et al.,49 reported the Diffucaps technology, the delivery 
system used for CER (Cyclobenzaprine Extended release), is a multi particulate bead 
system made up of multiple layers of drug, excipients, and release-controlling 
polymers. The beads can contain a layer of organic acid or alkaline buffer to control a 
drug’s solubility by creating an optimal pH micro environment. Alternatively, 
Diffucaps beads can contain a solid solution of drug and crystallization inhibitor to 
enhance bio availability by maintaining the drug in its amorphous state. The 
Diffucaps beads contained in each CER capsule are made by coating an inert core 
(such as sugar) with a layer of the active drug, Cyclobenzaprine, and then by applying 
a sealcoat and rate-controlling membrane. The beads are small, approximately 1mm 
or less in diameter, and individual capsule shells are filled with sufficient quantity of 
these to yield a 15- or 30-mg dose of CER.  
 T. Farrell, Ph.D. et al., (2007)50 reported the Development of a Common 
Cyclobenzaprine Formulation for Both Encapsulation and Tabletting Using Star Cap 
1500. The combination of star cap 1500/MCC is suitable to provide good 
compactibility characteristic to the formula and fast disintegration/dissolution to the 
film coated tablets. The satisfactory content uniformity of the capsules and tablets was 
achieved as a result of the excellent flow properties of the final blend and minimum 
potential segregation of the active ingredients during process. The in-vitro 
performance of capsules and film coated tablets has been proved similar with a 
complete release in the first 15 minutes of the dissolution profiles. 
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3. DRUG & EXCIPIENTS PROFILE 
3.1. DRUG PROFILE 
 
CYCLOBENZAPRINE HYDROCHLORIDE51-57 
3.1.1. Introduction: 
 Cyclobenzaprine hydrochloride is a newer centrally acting skeletal muscle 
relaxant for oral administration and it is used for the relief of muscle spasm associated 
with acute, painful musculoskeletal conditions. 
Synonym             :  Cyclobenzaprine hydrochloride 
      Chemical Name : 
Dimethyl(3-{tricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-
2-ylidene}propyl)amine 
Molecular formula      : C20 H21 N.HCL 
Structure: 
 
Structure of Cyclobenzaprine Hydrochloride 
Molecular weight  : 311.9 g/mol. 
CAS number   :  305-53-7 
Brand names               :  Bonelax®, Amrix®. 
Biopharmaceutical classification system: 
According to the BCS classification it belongs toClass - III 
     Pka value                       :  8.47 
Chapter - 3 
Drug Profile
`Department of Pharmaceutics, The Erode College Of Pharmacy & Research Institute 	

     Category                         : Skeletal muscle relaxant (central) 
                                         Anti depressant agent (Tricyclic)  
Tranquilizing agent, 
Anti fibromyalgia agent. 
Legal status   : Rx Prescription only 
3.1.2. PHYSICO CHEMICAL PROFILE: 
Description: 
White crystalline odorless amine salt. 
Solubility: 
Freely soluble in water & alcohol,             
Sparingly soluble in isopropanol, 
Insoluble in hydrocarbon solvents. 
Melting point: 
By capillary method melts at217 0C  ( Melts between 215 to 219 0C ) 
3.1.3. PHARMACEUTICAL PROFILE: 
Dosage  : 15&30 mg capsules SR ( Bonelax, Amrix), 
5&10 mg tablets ( Flexeril), 
7.5 mg tablet ( Fexmid ) . 
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3.1.4. ANALYTICAL PROFILE: 
UV spectrophotometry: 
57
 
Determination of Cyclobenzaprine hydrochloride in its pure and in capsule 
dosage forms using spectrophotometric method in Ultraviolet region was reported. 
Cyclobenzaprine hydrochloride exhibits maximum absorption maxima at 290 nm in 
0.1N HCL. 
3.1.5. PHARMACOLOGICAL PROFILE:              
Mechanism of action: 
Cyclobenzaprine is a skeletal muscle relaxant which relieves muscle spasm of 
local origin (that is, problems originating in the muscle itself and not in the nerves 
controlling the muscles) without interfering with muscle function. It does not directly 
act on the neuromuscular junction or the muscle but relieves muscle spasms through a 
central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin 
receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by 
decreasing the activity of descending serotonergic neurons. Like other tri cyclic anti 
depressants, Cyclobenzaprine exhibits anticholinergic activity, potentiation of nor 
epinephrine, and antagonism of reserpine. 
Cyclobenzaprine activates the locus cerelus in the brain stem leading to an 
increased release of nor epinephrine in the ventral horn of the spinal cord & 
subsequent inhibitory action of nor epinephrine on alpha motor neurons. 
Cyclobenzaprine has been considered structurally related to the first 
generation Tricyclic antidepressants. Such Tricyclics including amitriptyline act to 
inhibit the uptake of nor epinephrine, resulting in increased trans synaptic or 
epinephrine concentration. They have been shown to exert analgesic effect in chronic 
nerve & muscle pain. Cyclobenzaprine may have a similar effect. 
Pharmacokinetic properties: 
Biological Half life : 8 – 18 hours. 
Absorption:  
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Slowly but well absorbed after oral administration. 
Immediate release (IR): 
 Mean oral bioavailability ranges from 33% to 55%. Reaches steady state in 
approximately 3 to 4 days following 3 times a daily dosing. Cmax is approximately 80 
to 319 ng/ml. 
Extended release (ER): 
 Tmax is 7 to 8 hours. 
 Cmax is 8 to 20 ng/ml. 
 AUC is 354 to 780 ng.h/ml. 
Distribution: 
Highly bound to plasma proteins (93%).  
Metabolism: 
 Extensively metabolized, primarily to glucuronide like conjugates (hepatic 
& intestinal). 
Elimination: 
IR: 
  Excreted primarily via kidneys. The t1/2 is approximately 8 to 37 hours. 
ER: 
  The t1/2 is approximately 33 hours. 
Clearance: 
 0.7L/min. 
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Pharmacodynamics: 
  Cyclobenzaprine, closely related to the anti depressant amitriptyline, is used as 
a skeletal muscle relaxant to reproduce pain and tenderness and improve mobility, 
unlike dantrolene. Cyclobenzaprine cannot be used to treat muscle spasm secondary 
to cerebral or spinal cord disease.                 
 Like other Tricyclic antidepressants, Cyclobenzaprine exhibits anti-
cholinergic activity, potentiation of nor epinephrine, and antagonism of reserpine. 
Drug interactions: 
Cyclobenzaprine hydrochloride extended-release capsules may have life-
threatening interactions with MAO inhibitors. Cyclobenzaprine hydrochloride 
extended-release capsules may enhance the effects of alcohol, barbiturates, and other 
CNS depressants. Tricyclic antidepressants may block the antihypertensive action of 
guanethidine and similarly acting compounds. Tricyclic antidepressants may enhance 
the seizure risk in patients taking tramadol (ULTRAM® [tramadol HCl tablets, 
Ortho-McNeil Pharmaceutical] or ULTRACET® [tramadol HCl and acetaminophen 
tablets, Ortho-McNeil Pharmaceutical]). 
Therapeutic use: 
  Cyclobenzaprine hydrochloride is most commonly used as skeletal muscle 
relaxant (central acting) for relief of muscle spasm associated with acute, painful 
musculoskeletal conditions. 
Dosage & administration: 
Cyclobenzaprine HCl supplied as 15mg and 30mg capsules for oral 
administration. The recommended initial dose of the drug is one (1) 15 mg capsule 
taken once daily. Some patients may require up to 30 mg/day, given as one (1) 30 mg 
capsule taken once daily or as two (2) 15 mg capsules taken once daily. It is 
recommended that doses be taken at approximately the same time each day.   
Indications: 
Cyclobenzaprine hydrochloride extended-release capsules is indicated as an 
adjunct to rest and physical therapy for relief of muscle spasm associated with acute, 
painful musculoskeletal conditions. Improvement is manifested by relief of muscle 
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spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation 
of motion. 
Cyclobenzaprine hydrochloride extended-release capsules should be used only 
for short periods (up to two or three weeks) because adequate evidence of 
effectiveness for more prolonged use is not available and because muscle spasm 
associated with acute, painful musculoskeletal conditions is generally of short 
duration and specific therapy for longer periods is seldom warranted. 
Cyclobenzaprine hydrochloride extended-release capsules have not been 
found effective in the treatment of spasticity associated with cerebral or spinal cord 
disease or in children with cerebral palsy. 
Over dose: 
Although rare deaths may occur from over dosage with Cyclobenzaprine HCl. 
Multiple drug ingestion (including alcohol) is common in deliberate Cyclobenzaprine 
overdose. As management of over dose is complex and changing, it is recommended 
that the physician contact a poison control center for current information on treatment. 
Signs and symptoms of toxicity may develop rapidly after Cyclobenzaprine overdose, 
therefore, hospital monitoring is required as soon as possible. The acute oral LD50 of 
Cyclobenzaprine HCl is approximately 338 and 425 mg/kg in mice and rats, 
respectively.             
 
Overdose symptoms: 
The most common effects associated with Cyclobenzaprine overdose are 
drowsiness and tachycardia. Less frequent manifestations include tremor, agitation, 
coma, ataxia, hypertension, slurred speech, confusion, dizziness, nausea, vomiting, 
and hallucinations. Rare but potentially critical manifestations of overdose are cardiac 
arrest, chest pain, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic 
malignant syndrome 
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Adverse effects: 
  Among the most common side effects of Cyclobenzaprine are drowsiness 
(which occurs in between 1 in 6 and 1 in 3 persons), dry mouth (between 1 in 14 and 
1 in 4), and dizziness (between 1 in 30 and 1 in 9). Other reported side effects, for 
which the incidence is less than 1 in 30, include nausea, tiredness, constipation, 
blurred vision, unpleasant taste, nervousness, confusion, and abdominal pain or 
discomfort. 
Pregnancy 
Reproduction studies have been performed in rats, mice, and rabbits at doses 
up to 20 times the human dose and have revealed no evidence of impaired fertility or 
harm to the fetus due to Cyclobenzaprine. There are, however, no adequate and well-
controlled studies in pregnant women. Because animal reproduction studies are not 
always predictive of human response, this drug should be used during pregnancy if 
the physician feels that it is necessary. 
Nursing Mothers 
It is not known whether this drug is excreted in human milk. Because 
Cyclobenzaprine is closely related to the Tricyclic antidepressants, some of which are 
known to be excreted in human milk, caution should be exercised when 
Cyclobenzaprine hydrochloride extended-release capsules are administered to a 
nursing woman. 
Pediatric Use 
Safety and effectiveness of Cyclobenzaprine hydrochloride extended-release 
capsules has not been studied in pediatric patients. 
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3.2 POLYMER PROFILE 
3.2.1. ETHYL CELLULOSE N-50 
58, 59       
Non proprietary names : 
             BP          : Ethyl cellulose 
                   USP NF    : Ethyl cellulose 
             Ph Eur    : Ethyl cellulosum       
 Synonyms: 
Aqua coat ECD; Aqualon; E 462; Ethocel; Surelease. 
Chemical Name and CAS Registry Number: 
Cellulose ethyl ether, [9004-57-3] 
Empirical formula:     C12H23O6 (C12H22O5) n C12H23O5 
Structural formula: 
 
 Description: 
A tasteless free flowing white to light tan colored powder. 
 Functional Categories: 
Coating agent; flavouring fixative; tablet binder; tablet filler; viscosity-
increasing agent.              
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Incompatibilities: 
Incompatible with paraffin wax and microcrystalline wax. 
Solubility : 
  Insoluble in water, glycerin and propylene glycol but insoluble in varying 
degrees in certain organic solvents, depending upon the ethoxyl content. The addition 
of 10-20% of a lower aliphatic alcohol to solvents such as ketones, esters and 
hydrocarbons can improve the solubility. 
Stability and storage condition: 
It is resistant to alkalis both dilute and concentrated and to salt solutions. It is 
more sensitive to acidic materials than are cellulose esters. However the material can 
withstand dilute acids for a limited period of exposer. Ethyl cellulose is subject to 
oxidative degradation in the presence of sunlight or UV light at elevated temperatures. 
This may be prevented by use of an antioxidant and a compound with light absorption 
properties between 230-340 nm. Ethyl cellulose should be stored between 70C and 
320C in a dry area away from all sources of heat. Store in a well closed container. 
Types: 
35
 
Ethyl cellulose is available as four ethoxyl types depends on ethoxyl content. 
Each of these ethoxyl types is subdivided into viscosity types. The viscosity 
designation indicates the nominal viscosity in centipoises for a 5% weight 
concentration in the standard viscosity solvent (5% ethyl cellulose in 80% toluene: 
20% ethanol by weight). 
Type                                      Ethoxyl Content 
K-Type                                        45.0-47.2 
N-Type                                        48.0-49.5 
T-Type                                        49.6-51.5 
X-Type                                        50.5-52.5 
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Grade                                        Viscosity Range, cps  
 N-7                                                      5.6-8.0 
 N-10                                                    8.0-11.0 
N-14                                                     12.0-16.0 
N-22                                                     18.0-24.0 
N-50                                                     40.0–52.0 
N-100                                                   80.0–105.0  
Applications in Pharmaceutical Formulation: 
Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. 
The main use of ethyl cellulose in oral formulations is as hydrophobic coatings are 
used to modify the release of a drug, mask the taste, or to improve the stability of a 
formulation; for example, where granules are coated with ethyl cellulose to inhibit 
oxidation.               
            Ethyl cellulose dissolved in an organic solvent or solvent mixture, can, be used 
on its own to produce water insoluble films. Higher-viscosity ethyl cellulose grades 
tend to produce stronger and more durable films. Ethyl cellulose films may be 
modified to alter their solubility, by the addition hypromellose or a plasticizer. An 
aqueous polymer dispersion (or latex) of ethyl cellulose such as aquacoat ECD (FMC 
biopolymer) or surelease (colorcon) may also be used to produce ethyl cellulose films 
without the need for organic solvents. 
Drug release through ethyl cellulose-coated dosage forms can be a slow 
process unless a large surface area (e.g. Pellets or granules compared with tablets) is 
utilized. In those instances, aqueous ethyl cellulose dispersions are generally used to 
coat granules or pellets. Ethyl cellulose-coated beads and granules have also 
demonstrated the ability to absorb pressure and hence protect the coating from 
fracture during compression. Studies have also suggested ethyl cellulose for use in 
floating micro particles based on low density foam powder, for gastro retentive drug 
delivery systems. 
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Use       Concentration 
Microencapsulation                                                 10.0-20.0 
Sustained-release coating                                          3.0-20.0 
Tablet coating                                                            1.0-3.0 
Tablet granulation                                                      1.0-3.0 
3.2.4. HYPROMELLOSE (HPMC) 
62
   
Non-proprietary Names 
            BP       : Hypromellose 
            JP        : Hydroxypropylmethylcellulose 
            PhEur  : Hypromellosum 
            USP     : Hypromellose 
 Synonyms 
Benecel MHPC; E464; hydroxy propyl methyl cellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; Methyl hydroxy propyl cellulose; Metolose; 
Tylopur. 
Chemical Name and CAS Registry Number 
Cellulose hydroxy propyl methyl ether [9004-65-3] 
Empirical Formula and Molecular Weight 
    O methylated and O-(2-hydroxypropylated) cellulose, 10000 – 150000 
 Structural Formula 
 
Where R is H, CH3, or CH3CH (OH) CH2 
Functional Category 
Coating agent, film former, rate-controlling polymer for sustained release, 
stabilizing agent, suspending agent, tablet binder, viscosity increasing agent.   
 
Description 
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             Hypromellose is an odorless and tasteless, white or creamy- white fibrous or 
granular powder. 
Melting point 
Browns at 190–2008C; chars at 225–2300C. 
Glass transition temperature is 170–1800C. 
Solubility 
Soluble in cold water, forming a viscous colloidal solution, practically 
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol 
and dichloromethane, and mixtures of water and alcohol. Certain grades of 
hypromellose are soluble in aqueous acetone solutions, mixtures of dichloromethane 
and propan-2-ol, and other organic solvents. 
 
Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is non-
ionic, hypromellose will not complex with metallic salts or ionic organics to form 
insoluble precipitates.  
Stability and storage conditions 
Hypromellose powder is a stable material, although it is hygroscopic after 
drying. Solutions are stable at pH 3-11. Increasing temperature reduces the viscosity 
of solutions. Hypromellose undergoes a reversible sol-gel transformation upon 
heating and cooling, respectively. The gel point is 50-900C, depending upon the grade 
and concentration of material. 
Aqueous solutions are comparatively enzyme-resistant, providing good 
viscosity stability during long-term storage. However, aqueous solutions are liable to 
microbial spoilage and should be preserved with an anti microbial preservative. When 
hypromellose is used as viscosity-increasing agent in ophthalmic solutions, 
benzalkonium chloride is commonly used as the preservative. 
Hypromellose powder should be stored in a well-closed container, in a cool, 
dry place. 
Typical viscosity values for 2% (w/v) aqueous solutions of Methocel (Dow 
Chemical Co.). Viscosities measured at 200C.  
Methocel product                               Nominal viscosity 
 (mPas) 
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Methocel K100 Premium LVEP    100 
Methocel K4M Premium     4000 
Methocel K15M Premium     15 000 
Methocel K100M Premium     100 000 
Methocel E4M Premium     4000 
Methocel F50 Premium     50 
Methocel E10M Premium CR    10 000 
Methocel E3 Premium LV     3 
Methocel E5 Premium LV     5 
Methocel E6 Premium LV     6 
Methocel E15 Premium LV     15 
Methocel E50 Premium LV     50 
Applications in pharmaceutical Formulation 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, hypromellose is primarily used as a tablet binder, film 
coating, and as a matrix for use in extended release tablet formulations. 
Concentrations between 2% and 5% w/w may be used as binder in either wet or dry 
granulation process. High-viscosity grades may be used to retard the drug release of 
drugs from a matrix at levels of 10-80% w/w in tablets and capsules. 
Depending upon the viscosity grade, concentrations of 2-20% w/w are used 
for film-forming solution to film-coat tablets. Lower-viscosity grades are used in 
aqueous film-coating solutions, while higher-viscosity grades are used with organic 
solvents.  
Hypromellose is also used as an emulsifier, suspending agent, and stabilizing 
agent in topical gels and ointments. In addition, hypromellose is used is used in the 
manufacture of capsules, as wetting agent for hard contact lenses. It is also widely 
used in cosmetics and food products. 
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3.3 EXCIPIENTS PROFILE
 
3.3.1. POLYVINYL PYRROLIDINE (PVP K-30) 
60
 
Nonproprietary names: 
         BP       :  Povidone   
         JP        :  Povidone 
         Ph Eur :  Povidonum 
         USP     :  Povidone 
Synonyms : 
E 1201; kollidon; plasdone; polyvidone; polyvinylpyrrolidine; PVP
Chemical name and CAS registry number: 
1-Ethenyl-2-pyrrolidinone homopolymer,    [9003-39-8] 
Empirical Formula:  
 (C6H9NO)n 
Structural Formula: 

Molecular Weight            :           2,500 to 300,000 
Types:                  
PVP is characterized by its viscosity in aqueous solution, relative to that of 
water, expressed as a K-value in the range 10-120. 
Approximate molecular weights for different grades of povidone. 
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K-value                        Approximate molecular weight 
12                                              2 500 
15                                              8 000 
17                                              10 000 
25                                              30 000 
30                                              50 000 
60                                              400 000 
90                                              10 00 000 
120                                            30 00 000 
Description: 
   Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are 
manufactured by spray-drying and occurs as spheres. Povidone K-90 and higher K-
value povidones are manufactured by drum drying and occur as plates. 
Functional Category: 
 Disintegrant; dissolution aid; suspending agent; tablet binder 
Melting point: 
Softens at 1500C 
Solubility: 
Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water. Practically insoluble in ether, hydrocarbons, and mineral oil. In water, the 
concentration of a solution is limited only by the viscosity of the resulting solution, 
which is a function of the K-value. 
Stability and storage condition: 
Povidone darkens to some extent on heating at 1500C with a reduction in 
water solubility. It is stable to a short cycle of heat exposure around 110-1300C. 
Steam sterilization of an aqueous solution does not alter its properties. Aqueous 
solutions are susceptible to mold growth and hence require suitable preservatives. 
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Povidone can be stored under ordinary conditions without undergoing decomposition 
or degradation. However since the powder is hygroscopic, it should be stored in an air 
tight container in a cool, dry place.  
Incompatibilities: 
             Povidone is compatible in solution with a wide range of inorganic salts, 
natural and synthetic resins, and other chemicals. It forms molecular adducts in 
solution with sulfathiazole, sodium salicylate, salicylic acid, Phenobarbital, tannin, 
and other compounds. The efficacy of some preservatives e.g. thiomerosal, may be 
adversely affected by the formation of complexs with povidone. 
Applications in Pharmaceutical Formulation: 
Povidone is used in the form of a solution as a binder in tablet granulations. It 
is also added to powder blends in dry form and granulated insitu by the addition of 
water, alcohol, or water-alcohol. 
Use                                                                     Concentration (%) 
Carrier for drugs                                                  10–25 
Dispersing agent                                                  Up to 5 
Eye drops                                                             2–10 
Suspending agent                                                 Up to 5 
Tablet binder, tablet diluent, or coating agent        0.5–5 
3.3.2. POLY ETHYLENE GLYCOL-6000 
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 Non proprietary Name 
       BP         : Macrogols 
       JP          : Macrogol 6000 
       PhEur    : Macrogola 
       USP NF : Polyethylene glycol 
 
Synonyms 
Carbo wax; Carbo wax sentry; Lipoxol; Lutrol E; PEG; Pluriol E; polyoxy 
ethylene glycol.               
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Chemical Name and CAS Registry Number 
- Hydro--Hydroxypoly-(oxy-1,2-ethanediyl),  [25322-68-3]  
Empirical formula 
              HOCH2 (CH2OCH2)n CH2OH 
              n=3 for PEG-6000 
Structural formula 
 
Molecular weight     :  7300-9300 (JP) 
Functional category : 
USP- Suppository base, solvent, tablet and/or capsule lubricant, ointment base. 
BP  - pharmaceutical aid.  
Description: 
Poly ethylene glycol as being an addition polymer of ethylene oxide and 
water. Poly ethylene grades 200-600 are liquids, 1000 and above are solids at ambient 
temperatures. 
Liquid PEGs (PEG 200-600)  
Clear, colorless or slightly yellow-colored, viscous liquids. The odor is slight 
but characteristic and the taste is bitter and slightly burning taste. PEG 600 can be 
solid at ambient temperatures. 
Solid PEGs (PEG >1000) 
The solid grades are white or off white in color and range in consistency 
between pastes and waxy flakes. They have a faint, sweet odor. Grades of PEG 6000 
and above are available as free-flowing milled powders.   
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Melting point: 
 PEG -6000: 55-630C 
Solubility: 
All grades are soluble in water and miscible in all proportions with other PEGs 
(after melting if necessary). Aqueous solutions of higher molecular weight grades 
may form gels. 
Liquid PEGs are soluble in alcohols, glycols, acetone, glycerin and benzene. 
Solid PEGs are soluble in methanol, ethanol(95%), acetone and 
dichloromethane. They are slightly soluble in ether and aliphatic hydrocarbons but 
insoluble in liquid paraffin, fats, mineral and fixed oils. 
Stability and storage conditions 
 Chemically stable in air and in solution. PEGs do not support microbial 
growth nor become rancid. Stainless steel, aluminum, glass or lined steel are preferred 
for storage of liquid and low molecular weight products. Moisture may be absorbed 
especially the grades of molecular weight less than 2000. These must be stored in 
well-closed containers. Aqueous solutions of PEGs can be sterilized by autoclaving or 
filtration. Sterilization of solid grades by heat at 1500C for 1 hr may induce oxidation 
darkening and the formulation of acidic degradation products. 
 Oxidation may occur if PEGs are exposed for long periods to temperatures 
exceeding 500C. Storage under nitrogen will reduce the possibility of oxidation. 
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Incompatibilities 
The chemical reactivity of polyethylene glycols is mainly confined to the two 
terminal hydroxyl groups, which can be either esterified or etherified. However, all 
grades can exhibit some oxidizing activity owing to the presence of peroxide 
impurities and secondary products formed by auto oxidation. Liquid and solid grades 
are incompatible with FD&C Red No.3 and Yellow No.5. Additionally the solid 
interact with FD&C Blue No.1 and Red No.1, 2&4 reactions occurs with lakes of the 
above dyes. 
Physical effects caused by polyethylene glycol bases include softening and 
liquefaction in mixtures with phenol, tannic acid, and salicylic acid. Discoloration of 
sulfonamides and dithranol can also occur and sorbitol may be precipitated from 
mixtures. Plastics, such as polyethylene, phenol formaldehyde, polyvinylchloride, and 
cellulose-ester membranes (in filters) may be softened or dissolved by polyethylene 
glycols. Migration of polyethylene glycol can occur from tablet film coatings, leading 
to interaction with core components. 
Applications in Pharmaceutical Formulation            
Polyethylene glycols (PEGs) are widely used in a variety of pharmaceutical 
formulations including parenteral, topical, ophthalmic, oral, and rectal preparations. It 
has been used experimentally in biodegradable polymeric matrices used in controlled-
release systems. Aqueous polyethylene glycol solutions can be used either as 
suspending agents or to adjust the viscosity and consistency of other suspending 
vehicles. When used in conjunction with other emulsifiers, polyethylene glycols can 
act as emulsion stabilizers. 
  In solid-dosage formulations, higher-molecular-weight polyethylene glycols 
can enhance the effectiveness of tablet binders and impart plasticity to granules. 
However, they have only limited binding action when used alone, and can prolong 
disintegration, a mixture of the powdered constituents with 10–15% w/w PEG 6000 is 
heated to 70–750C. The mass becomes paste like and forms granules if stirred while 
cooling. This technique is useful for the preparation of dosage forms such as lozenges 
when prolonged disintegration is required. 
3.3.3. SUGAR SPHERES 
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Nonproprietary names 
BP         : Sugar spheres 
PhEur    : Sacchari sphere 
USP NF : Sugar spheres 
Synonyms: 
Non pareil, NPTAB, Nu-Core, Non-pareil seeds, PG sugar seeds, Sugar seeds, 
Nu-pariel PG, Suglets.  
Description:   
The USPNF 23 describes sugar spheres as approximately spherical granules of 
a labelled nominal-size range with a uniform diameter and containing not less than 
62.5% and not more than 91.5% of sucrose, calculated on the dried basis. The 
remainder is chiefly starch. The diameter of sugar spheres varies from 200 to 2000 
mm. 
Particle size distribution:  
Sugar spheres are of a uniform diameter. The following sizes are 
commercially available from various suppliers (US standard sieves): 
45–60 mesh (250–355 mm)                   25–30 mesh (610–710 mm) 
40–50 mesh (300–425 mm)                   20–25 mesh (710–850 mm) 
35–45 mesh (355–500 mm)                   18–20 mesh (850–1000 mm) 
35–40 mesh (420–500 mm)                   16–20 mesh (850–1180 mm) 
30–35 mesh (500–600 mm)                   14–18 mesh (1000–1400 mm) 
Functional categories:  
Tablet and Capsule diluent. 
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Solubility:  
Solubility in water varies according to the sucrose to starch ratio. The sucrose 
component is freely soluble in water, where as the starch component is practically 
insoluble in cold water 
Stability and storage conditions: 
Sugar spheres   are stable   when stored in a well-closed container in a cool, 
dry place. 
Method of manufacture: 
Sugar spheres are prepared from crystalline sucrose, which is cored using 
sugar syrup and a starch dusting powder. 
Applications: 
Sugar spheres are mainly used as inert cores in capsule and tablet 
formulations, particularly multi particulate sustained release formulations. They form 
the base upon which a drug is coated, usually followed by a release-modifying 
polymer coating. 
Complex drug mixtures contained within a single-dosage form may be 
prepared by coating the drugs onto different batches of sugar spheres with different 
protective polymer coatings. 
It is used as a starting core for drug loading on pellets. 
3.3.4. SUCROSE
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Non proprietary names: 
 IP  : Sucrose 
 JP  : Sucrose  
PhEur  : Saccharum              
 USP NF : Sucrose 
 
Excipients profile
Department of Pharmaceutics, The Erode College Of Pharmacy & Research Institute 

Synonym: 
         Beet sugar, Cane sugar, refined sugar, saccharose, sugar               
Chemical name and CAS Registry number: 
   -D-fructofuranosyl-  -D-glucopyranoside     [57-50-1] 
Empirical formula and molecular formula:  C12H22O11, 342.30 
Functional category 
Base for medicated confectionery; coating agent; granulating agent; sugar 
coating adjunct; suspending agent; sweetening agent; tablet binder; tablet and capsule 
diluent; tablet filler; viscosity-increasing agent                    
Description 
Sucrose is a sugar obtained from sugar cane (saccharum officinarum), sugar 
beet (Beta vulgaris), and other sources. It contains no added substances. Sucrose 
occurs as colourless crystals, as crystalline masses or blocks, or as a white crystalline 
powder; it is odourless and has a sweet taste.    
Melting point: 
 160-1860C (with decomposition) 
Stability and storage conditions 
Sucrose has good stability at room temperature and at moderate relative 
humidity .It absorbs up to 1% moisture, which is released up to heating up to 
900C.Sucrose caramelizes when heated to temperatures above 1600C
Incompatibilities 
Powdered sucrose may be contaminated with traces of heavy metals, which 
can lead to incompatibility with active ingredients e.g. ascorbic acid. 
 
 
Excipients profile
Department of Pharmaceutics, The Erode College Of Pharmacy & Research Institute 

Applications in pharmaceutical formulations 
Sucrose is widely used in pharmaceutical preparations syrup containing 50 -
67% sucrose is used in tabletting as a binding agent for wet granulation in the 
powdered form, sucrose serves as a dry binder (2–20% w/w )or as a bulking agent and 
sweetener in chewable tablets and lozenges. Sucrose syrups are also widely used as 
vehicles in oral liquid dosage forms to enhance palatability or to increase viscosity. 
Use                                                     Concentration (% w/w) 
Syrup for oral liquid formulations   67 
Sweetening agent     67 
Tablet binder (dry granulation)   2–20 
Tablet binder (wet granulation)   50–67 
Tablet coating (syrup)     50–67 
 
3.3.5. COLLOIDAL SILICONE DIOXIDE (Aerosil) 
65 
Nonproprietary Names  
BP   :  Colloidal anhydrous silica  
PhEur   :           Silica colloidalis anhydrica  
USPNF  :  Colloidal silicon dioxide  
Synonyms  
Aerosol; Cab – O – Sil M-5P; colloidal silica; fumed silica; light anhydrous 
silicic acid: silicle; silicic anhydride; silicon dioxide fumed; wacker HDK.  
Chemical Name & CAS Registry number    
            Silica   [7631-86-9]    
Empirical formula        : SiO2               
Structural Formula       :    SI02 
Molecular Weight         :     60.08 
Functional Category: 
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Adsorbent; anti caking agent; glidant; suspending agent; tablet disintegrant; 
viscosity – increasing agent, thermal stabilizer  
Description: 
Colloidal silicon dioxide is a sub microscopic fumed silica with a particle size 
of about 15 nm. It is a light, loose, bluish-white colored, odourless, tasteless, non 
gritty amorphous powder. 
Stability and storage conditions: 
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water 
without liquefying. When used in aqueous systems at a pH 0–7.5, colloidal silicon 
dioxide is effective in increasing the viscosity of a system.           
However, at a pH greater than 7.5 the viscosity-increasing properties of 
colloidal silicon dioxide are reduced; and at a pH greater than 10.7 this ability is lost 
entirely since the silicon dioxide dissolves to form silicates. Colloidal silicon dioxide 
powder should be store in a well-closed container. 
Some grades of colloidal silicon dioxide have hydrophobic surface treatments 
that greatly minimize their hygroscopicity. 
Incompatibilities: 
              Incompatible with diethylstilbestrol preparations    
Solubility:      
                Practically insoluble in organic solvents, water, and acids, except 
hydrofluoric acid; soluble in hot solutions of alkali hydroxide. Forms a colloidal 
dispersion with water.              
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Applications in Pharmaceutical formulation of Technology: 
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics and 
food products.  Its small particle size and large specific surface area give it desirable 
flow characteristics which are exploited to improve the flow properties of dry 
powders in a number of processes, e.g. tableting. 
 Colloidal silicon dioxide is also used to stabilize emulsion and as a thixotropic 
thickening and suspending agent in gels and semisolid preparations. With other 
ingredients of same refractive index transparent feels may be formed.  The degree of 
viscosity increase depends on the polarity of the liquid (polar liquids generally require 
a greater concentration of colloidal silicon dioxide than nonpolar liquids). Viscosity in 
largely independent of temperature.  However, changes to the pH of a system may 
affect the viscosity.  
Use                                                  Concentration (%) 
Aerosols     0.5–2.0 
Emulsion stabilizer    1.0–5.0 
Glidant     0.1–0.5 
Suspending and thickening agent  2.0–10.0  
3.3.6. TALC: 
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Non proprietary names: 
BP : Purified talc 
JP : Talc 
PhEur : Talcum 
  USP : Talc 
Synonyms:    
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore.  
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Chemical Name and CAS Registry Number: 
 Talc [14807-96-6]  
Empirical formula: 
Mg6 (Si2O5)4(OH)4 
Functional Category:  
Anti caking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Description:    
Talc is a very fine, white to greyish-white, odourless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Stability and storage conditions 
Talc is a stable material and may be sterilized by heating at1600C for not less 
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibilities 
Incompatible with quaternary ammonium compounds. 
Moisture content 
Absorbs insignificant amounts of water at 250C and relative humidities up to 
about 90%                                                       
Particle size distribution         
Varies with the source and grade of material. Two typical grades are 99% 
through a 74 µm (#200mesh) or 99% through a 44 µm (#325 mesh).                                                    
Solubility                                         
Practically insoluble in dilute acids and alkalies, organic solvents, and water. 
Melting range    
17-1500C (commercial samples) 
126-1300C (highly pure) 
Applications   
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Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluents, although today it is less commonly used. However it is widely Used as a 
dissolution retardant in the development of controlled release products, also used as a 
lubricant in tablet formulations, in a novel powder coating for extended-release 
pellets, and as an adsorbent. 
In topical preparations, talc is used as a dusting powder, although it should not 
be used to dust surgical gloves. Talc is a natural material, it may therefore frequently 
contain microorganisms and should be sterilized when used as a dusting powder. 
Use                                       Concentration (%) 
Dusting powder                      90.0–99.0 
Glidant and tablet lubricant    1.0–10.0 
Tablet and capsule diluents     5.0–30.0  
3.4. SOLVENTS PROFILE 
3.4.1. Isopropyl alcohol 
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Non proprietary Name:  
BP       : Isopropyl alcohol 
JP        : Isopropanol 
PhEur  : Alcohol isopropylicus 
USP     : Isopropyl alcohol 
Synonyms: 
Isopropanol, alcohol Isopropylieum, petrohol, dimethylcarbinol, 2-propanol, 
IPA,  
Chemical Name and CAS Registry Number: 
Propran-2-ol [67-63-0] 
Empirical formula  : C3H8O 
Molecular weight  : 60.1g 
Melting point   : 88.50C 
Functional Categories: 
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Solvent, disinfectant. 
Description: 
Isopropyl alcohol is a clear, colourless, mobile, volatile, flammable liquid with 
a characteristic, spirituous odour resembling that of a mixture of ethanol and acetone; 
it has a slightly bitter taste.               
Stability and storage condition: 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
 
Solubility: 
Miscible with benzene, chloroform, ethanol (95%) ether, glycerine, and water. 
Soluble in acetone. Insoluble in salt solutions. Forms an azeotrope with water 
containing 87.4% w/w isopropyl alcohol (boiling point 80.370C). 
Incompatibilities: 
Oxidizing agents like hydrogen peroxide and nitric acid decompose isopropyl 
alcohol. It may be slated out form aqueous mixtures by the addition of sodium 
chloride, sodium sulfate and other salts or by sodium hydroxide. 
Applications in Pharmaceutical Formulation: 
Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical 
formulations primarily as a solvent in topical formulations. It is used in lotions the 
marked degreasing properties may limit its usefulness in preparations used repeatedly.  
It is also used as a solvent both for tablet film-coating and for tablet granulation. 
Isopropyl alcohol has some antimicrobial activity and a 70% v/v aqueous solution is 
used as a topical disinfectant. It has also been shown to significantly increase the skin 
permeability of nimesulide from carbomer. Therapeutically, isopropyl alcohol has 
been investigated for the treatment of postoperative nausea or vomiting.  
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4. AIM & OBJECTIVE OF THE WORK 
 AIM : 
Cyclobenzaprine hydrochloride is a centrally acting skeletal muscle agent used 
in the relief of muscle spasm associated with acute, painful musculoskeletal 
conditions, as tranquilizing agent and as anti depressant.                        
The oral bioavailability of Cyclobenzaprine hydrochloride is 33-55%. In 
normal course of Therapy drug administration is required every 3-6hrs, thus warrants 
the use of sustained Release formulation for prolong action and to improve patient 
compliance. 
Thus the aim of the present study was to develop a sustained release 
formulation of Cyclobenzaprine hydrochloride pellets using powder layering 
technique. The drug release profile of the test product was to mapped against 
innovator product. 
The concept of drug delivery has been explored for the delivery of drugs for 
prolonged period of time for the past few years. This type of drug delivery has proved 
to provide a solution to several problems encountered in the repeated administration 
of such drugs. Utilizing the concept of incorporating drug into the polymer matrices 
and extend the drug release for prolong period of time, an attempt was made to design 
and evaluate sustained release pellets of Cyclobenzaprine hydrochloride. 
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The Object of the present work was: 
• To formulate a drug delivery system, which provided a sustained release of the 
drug that maintained the plasma drug concentration above the MEC for an 
extended period of 16 hours.  
• The dosing frequency was reduced by formulate into single capsule per day. 
• Even though in market Cyclobenzaprine hydrochloride tablets were available, 
this work was objected to formulate pellets because of pellets are having good 
flow properties and high degree of flexibility in the design and development of 
formulation. 
• Finally to provide the sustained drug delivery system which increases the 
patient compliance, effectiveness of therapy, reduces the chances of adverse 
effect and hyper sensitivity of reaction by maintaining the plasma drug 
concentration at the same level with in therapeutic range for the required 
period of time.   

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5. PLAN OF WORK 
  The following experimental protocol was designed to allow a systemic 
approach to the study 
1. Innovator product characterization. 
2. Preparation of calibration curve of Cyclobenzaprine Hydrochloride in 0.1N 
HCl 
3. Determination of λmax  of  Cyclobenzaprine Hydrochloride   
4.  Preformulation studies. 
   a) Physical Appearance 
   b) Solubility Studies 
   c) Melting Point 
    d) Physical Properties          
   5. Compatibility study of drug with excipients. 
   6. Formulation of sustained release Cyclobenzaprine HCl pellets. 
   7. Filling of drug pellets into capsules size no.4. 
   8. Evaluation of capsules 
   a) Weight variation test. 
   b) Friability test. 
   c) Locking length test. 
   d) Disintegration test. 
   e) Moisture content test    
   f) Assay. 
   g) In-vitro drug release studies. 
   h) Scanning Electron Microscopy (SEM) Of Optimized formulation. 
   9. Comparison of the formulations with reference. 
 10. In-vitro Release Kinetic models. 
 11. Accelerated Stability study of optimized formulation. 

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6. MATERIALS AND METHODS 
6.1. MATERIALS USED:  
Table No. 9: LIST OF CHEMICALS USED WITH THEIR SUPPLIER 
SL. 
NO 
MATERIALS 
SPECIFICATION MANUFACTURERS/ 
SUPPLIER 
1 Cyclobenzaprine HCl        USP Fleming laboratories, 
Hyderabad. 
2 Sugar spheres         IH Werner, USA. 
3 Sucrose blend      USP-NF Shiva sakthi, 
Hyderabad. 
5 Aerosil (colloidal silicon 
dioxide) 
     USP-NF Evonik, Germany. 
6 PVP – k30 (kollidon k30 
powder) 
     USP-NF BASF, Germany 
   7         HPMC E5 (Hydroxy  propyl 
methyl cellulose)  
     USP-NF Shine-E-tsu, Japan 
8 Ethyl cellulose N-50      USP-NF Feicheing, Chaina. 
9 PEG (poly ethylene 
glycol)6000 
     USP-NF Clarient. 
10 Talc      USP-NF Signet chemical 
corporaton, US. 
11 IPA (Iso propyl alcohol)      USP-NF Ra chem, Hyderabad. 
12 Purified water         USP Ra chem., Hyderabad. 
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6.2. INSTRUMENTS USED:   
Table No: 10 DETAILS OF EQUIPMENTS USED 
SR. 
NO. 
INSTRUMENT MANUFACTURER/SUPPLIER. 
1. Electronic Balance Sartorius, Germany.(ETD - 1020) 
2. Sifter Bright pharma machinary. 
3. Pulverizer Micro pulverizer. 
4 Blender  Sreenix.(SCLDC 1310) 
5 Coating pan Platinum pharma tech(pptc-18) 
6 Tray dryer  Millenium equipment pvt.ltd.(6G) 
7 Fluid bed coater Platinum pharma tech (RPT FBC 5) 
8 Friability Test Apparatus Roche TAR10 Friabilator. 
9. Vernier caliper Inox- somet. 
10. Disintegration apparatus 
Electro Lab.  
 
11 Dissolution apparatus 
Electro Lab.  
TDT - 14L 
12 
Double beam UV 
Spectrophotometer 
Shimadzu (UV – 2450). 
13 FTIR Spectrophotometer Perkin Elmer spectrum. 
14 Digital pH meter 
Eutech instruments. 
 
15 Automatic capsule filling machine Rimek formulations. 
16 Melting point apparatus. Kemi,Mumbai. 
17 Tapped density apparatus. Electrolab (ETD – 1020). 
18 Mechanical stirrer Vision labs. 
19 Hand held Sieve VWR Scientific 
20 Stability Chamber Thermo Lab 




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6.3. METHODS 
6.3.1. INNOVATOR DETAILS
68 
 Bonelax capsules are available in two strengths -15 mg, 30mg. 
Description: 
Dosage form and strength: 
API Characterization: 
Drug: Cyclobenzaprine Hydrochloride 
 Description of powder was determined. 
 Moisture content was determined. 
 Assay was determined by UV method. 
 Characteristics like bulk density, tapped density, compressibility index, 
hausner’s ratio and angle of repose were performed. 
With the help of analysis of the innovator product we will able to compare the 
results obtained of our formulated product and it was helpful for calculation of the (f1) 
dissimilarity & (f2) similarity dissolution factor. 
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6.3.2. Preparation of calibration curve of Cyclobenzaprine HCl in 0.1N HCl: 
Cyclobenzaprine Hydrochloride exhibits peak absorbance at 290 nm in 0.1 N 
HCl. Instrument used: Systronic Double beam UV Spectrophotometer. 
Procedure: 
Preparation of 0.1N HCl: 
 Pipette out 8.6 ml of concentrated hydrochloric acid and diluted to 1000ml 
with distilled water and stirred well. 
Procedure for calibration curve: 
 Weigh accurately 100mg of Cyclobenzaprine Hydrochloride and dissolve it in 
100 ml calibrated volumetric flask and completing volume with methanol (Primary 
stock solution). From the primary stock solution  pipette out 10ml into 100 ml 
calibrated volumetric flask and make up volume with 0.1N HCl. This is the secondary 
stock solution. 
 Several dilutions were made from this secondary solution, to obtain a 
concentration range of 5-25 µg/ml. The absorbance was measured at 290nm using 
0.1N HCl as blank and plotted to get the calibration curve.  
6.4. PREFORMULATION STUDIES
69 
A preformulation activity ranges from supporting discovery’s identification of 
new active agents to characterizing physical properties necessary for the design of 
dosage form. Critical information provided during preformulation can enhance the 
rapid and successful introduction of new therapeutics entities for humans. 
Preformulation testing is an investigation of physical and chemical properties of a 
drug substance.  
Preformulation studies are carried out with the objective of ascertaining the 
incompatibility of the excipients used in the existing formulation and to avoid any 
excipient, which is incompatible with the drug in the final formulation  
Objective: 
The overall objective of preformulation testing is to generate information 
useful in developing the formulation which is stable and bioavailable. Further the use 
of  Preformulation  parameters maximizes the chances in formulating an acceptable, 
safe, efficacious and stable product. For any drug substances to formulate into a 
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dosage form, it is necessary to study the physicochemical properties of the bulk drug 
like physical appearance, solubility, bulk density, tapped density, compressibility 
index, melting point, molecular weight, sieve analysis. 
a) Physical Appearance 
The appearance of the API was done by visual observation. 
b) Solubility studies 
72
 
 Drugs solubility is usually determined by the equilibrium solubility method by 
which an excess of drug is placed in a solvent and shaken at a constant temperature 
over long period until equilibrium is obtained. Chemical analysis of drug content in 
solution is performed to determine the degree of solubility using rotating shaker. 
c) Determination of Melting Point
70 
Melting point of Cyclobenzaprine Hydrochloride was determined by capillary 
method by using Mel-Temp melting point apparatus. 
e) Physical properties:  
Density
69
 
 Density of pellets can be affected by changes in formulation and or process 
variable. 
i) Bulk density: 
                  The bulk density of a powder is the weight of the powder divided by the 
volume it occupies, normally expressed as g/ml. Bulk density is important criteria as 
it can significantly affect fill volumes, can affect batch size determination during 
coating operation. The total volume includes particle volume, inter-particle void 
volume and internal pore volume. The bulk density of powders depends greatly on 
degree of compaction. 
ii) Tapped density: 
 It is defined as the maximum packing density of a powder (or blend of 
powder) achieved under the influence of well defined, externally applied forces. The 
minimum packed volume thus achieved depends on a number of factors including 
particle size distribution, true density, particle shape and cohesiveness due to surface 
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forces including moisture. Therefore, the tap density of a material can be used to 
predict both its flow properties and its compressibility. 
Method:                     
An accurately weighed quantity of the powder (W), was carefully poured into 
the graduated cylinder and the volume (Vo) was measured, then the graduated 
cylinder was closed with lid, set into the density determination apparatus. The density 
apparatus was set for 500 taps and after that, the volume (Vf) was measured and 
continued operation till the two consecutive readings were equal 
The bulk density, and tapped density were calculated using the following formulas: 
 Bulk density (o)    = W / Vo  
Tapped density (t) = W / VF 
Where, 
W = weight of the powder 
VO = initial volume 
VF = final volume 
 iii) Compressibility index (Carr’s index)
71 
  The bulk density and tapped density was measured and compressibility index 
was calculated using the formula. 
  %compressibility index = [(t-o)/t]×100 
Where,  
  t= tapped density,   o=bulk density.  
Table No. 11: Relation between % compressibility and flowability 
Compressibility index Type of flow 
10 Excellent  
11-15 Good  
16-20 Fair  
21-25 Passable  
26-31 Poor 
32-37 Very poor 
>38 Very very poor 
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iv) Hausner’s ratio 72 
  Hausner’s ratio was determined as the ratio between the tapped density to that 
of the bulk density. 
Hausner’s ratio= t/o 
 Where, 
  t = tapped density 
  o =bulk density  
Table No. 12 : Relation between Hausner’s Ratio and flowability 
Hausner’s ratio Type of flow 
1.00-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
>1.60 Very very poor 
v) Flow property 
73
 
  Flow property reflects suitability of material during filling operation. Also it 
reflects changes in particle size, shape, density, electrostatic charges and adsorbed 
moisture, which may arise from processing or formulation changes. 
  The more commonly used method to assess flow properties is angle of repose. 
Angle of Repose 
The flow characteristics are measured by angle of repose. Improper flow of 
powder is due to frictional forces between the particles.  These frictional forces are 
quantified by angle of repose. 
Angle of repose is defined as the maximum angle possible between the surface 
of a pile of the powder and the horizontal plane and is related to the density, surface 
area and shapes of the particles. Material with a low angle of repose forms flatter piles 
than material with a high angle of repose (Tan ). 
Tan =h/r 
Where,  
  h = height of the pile;  r = radius of the base of the pile 
Method:  
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A glass tunnel is held in place with a clamp on ring report over a glass plate, 
powder (weighed) and poured in tunnel keeping the orifice of tunnel blocked.  When 
powder is emptied from funnel, angle of heap to horizontal plane is measured with 
protector. Highet of pile (h) and radius of the base (r) is measured with ruler. Thus the 
angle of repose is measured.                          
Table No. 13: Relationship between angle of repose & powder flow 
Angle of repose Type of flow 
<20 Excellent 
20-30 Good 
30-34 Passable 
>40 Very poor 
 
6.5. DRUG-EXCIPIENT COMPATIBILITY STUDIES 
Compatibility studies were conducted to investigate and predict 
physicochemical interaction between drug substance (Cyclobenzaprine 
Hydrochloride) and excipients and therefore to select suitability of chemically 
compatible excipients. The shelf life of product or any other unwanted effects on the 
formulation determined by using suitable analytical techniques like FTIR, DSC. 
Procedure: 
1. Homogenous mixtures of drug and excipients were prepared. These mixtures 
were filled in a 5ml glass vials and self-seal LDPE bags and packed properly. 
2. These vials are exposed to 1) 25oC/60% RH 2) 40˚C / 75%RH. Observations 
for physical appearance are made at 0 week, 2nd week, and 4th week. The 
samples were withdrawn for analysis of following parameters by UV and KF 
Method. 
1) Appearance 
2) Moisture content 
3) Assay 
4) Related substances.  
 
Table No. 14: Protocol For drug-excipients compatibility study 
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S.No Composition Details 
Initial  physical 
description 
1 API White crystalline powder 
2 API + Sugar spheres(#24-#30) 
Off-white powder contain 
spherical pellets 
3 API+ Sucrose Powder Off-white powder 
4 API + Aerosil Off-white powder 
5 API + Pvpk-30   (1%) Off-White powder 
6 API + ethyl cellulose  N-50 Off-White powder 
7 API + HPMC E5 Off-white powder 
8 API+  Poly ethylene glycol 6000 
white powder contain 
crystalline material 
9 API +  Talc Off white crystalline powder 
10 API +  Isopropyl alcohol Off-white thick mass 
11 API +  Purified Water Off-white thick mass. 
12 
API + Sugar spheres +    Ethyl cellulose N-50+ 
HPMC 
E5+Polyethyleneglycol6000+Pvpk30+Talc+Aerosil 
+I.P.A + Sucrose +Purified Water. 
Off-white powder    
containing lumps 
All the samples mentioned above and initial samples were observed for 
physical characteristics.  
FTIR Spectroscopy: 
Compatibility study of drug with the excipients was determined by I.R. 
Spectroscopy (FTIR). The pellets were prepared at high compaction pressure of about 
12 psi for 3 minutes by using KBr and the ratio of sample to KBr is 1:100.The pellets 
thus prepare were mounted in a suitable holder in SHIMADZU IR spectrophotometer 
and the IR spectrum was recorded from 4000 cm-1 to 625 cm-1 in a scan time of 12 
minutes. The resultant spectra were compared for any spectral changes. 
 
Based on the above discussion and reference product, the following excipients 
were selected for product development. 
 
Table No. 15: Excipients for present formulation 
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S.No Excipient Functional category 
1 Sugar spheres Core material 
2 Aerosil Disintegrant 
3 Pvpk-30 Binder 
4 Ethyl cellulose  N-50 SR polymer 
5 HPMC Solubulizer 
6 Poly ethylene glycol 6000 Plasticizer 
7 Talc             Glidant 
8 Sucrose powder             Diluent 
9 Isopropyl alcohol             Vehicle 
10 Purified water             Vehicle 
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6.6. FORMULATION DEVELOPMENT
74
 
Based on preformulation data various excipients were selected and their 
compilation was shown in the below table. 
Table No. 16: Trail batches formulas and their quantities as per mg/capcule 
S.
No 
Ingredients                                              mg/capsule 
 Drug loading 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Cyclobenzaprin
e hydrochloride 30 30 30 30 30 30 30 30 30 
2 Sugar Spheres 
(#24 - 	30) 54.4 54.4 54.4 54.4 54.4 54.4 54.4 54.4 54.4 
3 Sugar powder 27.2 27.2 27.2 27.2 27.2 27.2 27.2 27.2 27.2 
4 Aerosil 
1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 1.36 
 Binder solution          
5 Sugar (10%) 1.02 1.02 1.02 1.02 1.02 1.02    __    __   __ 
6 Pvp k-30 (1%) 2.72 2.72 2.72 2.72 6.8 6.8 6.8 6.8 6.8 
7 Purified water Q.S Q.S Q.S Q.S Q.S Q.S   __   __   __ 
8 I.P.A __ __ __ __ __ __ Q.S Q.S Q.S 
 SR coating          
9 Ethyl cellulose 
N-50 
18.3
6  
(13.
5%) 
16.3
2   
(12
%) 
14.9
6 
(11
%) 
13.6 
(10) 
10.8
8 
(8%) 
11.5
6 
(8.5
%) 
12.2
4 
(9%) 
12.9
2 
(9.5
%) 
14.2
8 
(10.5
%) 
10 HPMC E5 2.04 2.04 2.04 2.04 1.38 1.38 1.38 1.38 1.38 
11 P.E.G-6000 1.83 1.63 1.63 1.63 1.29 1.29 1.29 1.29 1.29 
12 Talc __ __ __ __ 0.29 0.29 0.29 0.29 0.29 
13 I.P.A Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
14 Purified Water Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
 
Pellets were evaluated by physical and chemical parameters. Characteristics   
like bulk density, tapped density, compressibility index, Hausner’s ratio, angle of 
repose, sieve analysis and assay carried out. 
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Manufacturing process of Cyclobenzaprine HCl sustained release pellets: 
The manufacturing process involved in two stages 
1. Drug loading 
2. SR coating 
Drug loading: 
a) Blending 
b) Pulverization 
c) Binder solution preparation 
d) Pelletization 
e) Drying 
f) Sifting 
SR coating: 
a) Preparation of coating solution, 
b) Coating, 
c) Sifting. 
6.6.1. DRUG LOADING: 
a) Blending: 
Transfer Cyclobenzaprine hydrochloride, sugar blend and aerosol into 
blender one by one and blend the material for 15 minutes. Finally collect in in-
process container (IPC) lined with virgin double polyethylene bag. 
b) Pulverization: 
Pulverize the blended Cyclobenzaprine HCl with excipients through 
pulverizer fitted with 0.5mm screen and collect the material in-process container 
(IPC) lined with virgin double polyethylene bag.  
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c) Binder Solution Preparation: 
Take isopropyl alcohol in S.S vessel and slowly add PVP K-30 (kollidon k-
30) under continue stirring until to get clear solution. 
Filter the above solution through #200 mesh or nylon cloth. 
d) Pelletization: 
 Use No. #24 and No.#40 mesh. Check the mesh integrity before and after 
Sieving. 
 Sift the sugar spheres through #24 and #24 down pellets through #30 and 
collect retains and downs separately. Load the sugar spheres (#24 - #30) into 
coating pan and start the coating pan and allow the beads to rotate. 
 Adjust the compressed air pressure to 1.0-2.0 kg/cm2  
 Start the peristaltic pump and adjust to 10 – 40 RPM. 
 Start spraying the binder solution adjusting the gun distance (30-40cm). 
 Continue spraying until beads become wet 
 Stop spraying and add drug mixture in small quantities to the wet beads in the 
coating pan until the beads are free flowing. 
 Adjust the peristaltic pump to 20 – 80 RPM repeat the spraying of binder 
solution and powder addition till the completion of the drug mixture. 
 Note the parameters at every 30 minutes. 
e) Drying: 
 Check the cleanliness of trays of tray dryer and record. 
 Load the wet drug loaded pellets into tray drier trays and load the trays into 
tray drier. 
 Set the inlet temperature around 600c to get the bed temperature between 450-
500c        
 Unload the pellets after moisture content comes below 2.0% into the in-
process container. 
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f) Sifting: 
 Check the cleanliness of vibro sifter. Use No. #18 and #24 mesh. Check mesh 
integrity before and after sifting. Operate the vibro sifter. 
 Sift the dried pellets through #18 and collect #18 retains and passings 
separately. 
 Now pass #18 passings pellets through #24 and collect retains and passings 
separately.  
 Collect the sifted pellets (#18-#24) and RRS separately into the in-process 
container. 
6.6.2. S.R COATING: 
a) Preparation of Coating Solution: 
i)  Dissolve the ethyl cellulose N-50 in isopropyl alcohol with continuous 
stirring. 
ii) Then disperse the HPMC 6cps in the above IPA solution with continuous 
stirring. 
iii) Dissolve separately the PEG-6000 in purified water with continuous 
stirring and disperse talc in this solution. 
iv) Now add the solution of step – 3 into step - 2 with continuous stirring. 
v) Finally pass the above solution through #200 mesh or nylon cloth and 
collect the solution separately. 
b) Coating: 
 Operate the fluid bed coater and load the drug loaded pellets into FBC bowl. 
 Set the inlet temperature to 450-550C, bed temperature 400-450C. 
 Coat the drug loaded pellets by bottom spray (Wurster) at peristaltic pump 
rpm of 15-80 and atomizing air pressure of 3.0-5.0kg/cm2 with coating 
solution till the coating solution was completed. 
 Dry the pellets in FBC for about 15 minutes before unloading. 
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                                     Fig 17: Bottom spray coating 
c) Sifting: 
 Check the cleanliness of vibro sifter. Use No. #18 and #22 mesh. Check mesh 
integrity before and after sifting. Operate the vibro sifter. 
 Sift the dried pellets through #18 and collect #18 retains and passings 
separately. 
 Now pass #18 passings pellets through #22 and collect retains and gassings 
separately.  
 The sifted pellets (#18- #22) are collected into the in-process container (IPC). 
Packaging & Storage: 
Collect sifted Cyclobenzaprine HCl pellets (#18-#22) in HDPE container lined 
with double polyethylene bags. Transfer the HDPE containers into finished goods 
store and store below 250C. 
Cyclobenzaprine Hydrochloride sustained release capsules were prepared. The 
process was displayed in the below flow chart.  
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There are various in process control parameters should be performed. They are 
A) During drug layering:      
Appearance 
Average weight 
Weight uniformity 
Disintegration time   
B) During SR coating: 
Appearance    
Size of pellets by passing through Sieve 
Assay 
Coating process parameters 
Table No. 17: 
Parameters Laboratory Scale  
Equipment Partitions: Number/Diameter 
Number of Spray Guns  
7” Wurster 1/89 mm/1  
Batch size  1 kg   
Coating process parameters  
Fluidizing air volume (CFM)  320 -650 
Inlet air temperature (ºC)  50-55 
Product bed temperature (ºC)  40-45  
Spray rate (g/min)  15-30  
Atomizing air pressure (bar) 3.0 – 5.0 
Coating Efficiency  99%  



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6.7. FILLlING OF CYCLOBENZAPRINE HYDROCHLORIDE PELLETS IN 
CAPSULES 
To prepare Cyclobenzaprine Hydrochloride capsules 30 mg by taking 
Cyclobenzaprine Hydrochloride pellets from the formulation F8 and filled. 
Procedure 
1. Before filling pellets into capsules the parameters like bulk density, tapped 
density, compressibility index, angle of repose, Hausner’s ratio is evaluated. 
2. Size‘4’ capsules were selected for capsule formulation which has dark blue 
color body and dark blue color cap. 
3. The coated pellets were transferred into capsules by spreading it into equal 
quantities equivalent to 30mg of Cyclobenzaprine Hydrochloride by 
Automatic capsule filling machine. 
6.8. EVALUATION TESTS: 
     All the prepared capsules were evaluated for following parameters.                     
6.8.1. Weight variation test: 
 The uniformity of dosage units may be demonstrated by determining weight 
variation and/or content uniformity. The weight variation method is as follows. 
Individual weights of 10 capsules were taken and the average weight was 
calculated by using the following formula.  
                                (Weight of capsule-Average weight)   
Weight variation = ----------------------------------------------- ×100 
                                      Average weight of capsules 
Weight variation should not be more than 5 %. 
6.8.2 Friability test: 
  It is necessary to attain acceptable friability of pellets that can withstand 
handling, shipping, storage and operations like coating and filling. Friability is 
strongly affected by type and amount of binder used. It is affected by method of 
processing. 
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Friability is generally determined by use of Roche TAR 10 frabilator (Erweka, 
Ensenstam, Germany). It involves placing measured weight of pellets(accurately 
5grams) in the friabilator and rotating /tumbled for a predetermined number of 
revolutions(200) at 25 rpm along with 12 steel balls(diameter 8.5mm, weighing 2.487 
gm each) as attrition agents. After friability testing the pellets were sieved 
(mesh#30).The weight loss(%F) after friability testing was calculated by the formula  
%F= (wi - wr) X100/wr 
  Where wi is the initial weight of the pellets before friability testing, and wr was 
the weight of the pellets retained above the sieve (aperture size0.355mm) after 
friability testing. All parameters were evaluated for 6 times (n=6) 
6.8.3 Locked length
 
It was tested by using vernier calipers. 
6.8.4 Disintegration 
The compendial disintegration test for hard and soft capsules follows the same 
procedure and uses the same apparatus described later in this chapter for uncoated 
tablets. The capsules are placed in the basket rack assembly, which is repeatedly 
immersed 30 times per minute into a thermostatically controlled fluid at 37ºc and 
observed over the time described in the individual monograph. To fully satisfy the 
test the capsules disintegrate completely into a soft mass having no palpably firm 
core, and only some fragments of the gelatin shell.  
6.8.5 Moisture Content (By kf method method): 
             Take about 30 ml of the dried methanol in the KF titration flask and titrate 
with KF reagent until the end point to make inside of the flask water free. Finely 
powder pellets of Cyclobenzaprine hydrochloride. Transfer quickly an accurately 
weighed quantity of about 0.5gm of sample to the titration flask and dissolve by 
stirring and titrate with KF reagent to the end point and calculate % water content by 
following formula. 
 
Calculation: 
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 % Moisture content= V x F x 100 / V x 1000 
Where,  
 V= Volume of KF consumed for sample reading, 
 F= Factor for KF reagent, 
W= Weight of sample in g. 
6.8.6 Assay (By UV): 
Standard preparation: 
 Transfer about 25 mg of Cyclobenzaprine hydrochloride, accurately weighed, 
to a 100ml volumetric flask add 70ml of ethanol, sonication for 10 minutes and dilute 
with methanol to volume. Mix and filter. Transfer 2.o ml of this solution to 50 ml 
volumetric flask, dilute with methanol to the volume and mix. 
Sample preparation: 
 Powder the pellets and transfer an accurately weighed quantity of the powder 
equivalent  to about 25 mg of Cyclobenzaprine hydrochloride to a 100ml volumetric 
flask, add 70 ml of methanol, sonicate for 30 minutes and cool the solution to room 
temperature dilute with methanol to volume. Mix and filter. Transfer 2.0 ml of this 
solution to a 50 ml volumetric flask, dilute with methanol to volume and mix. 
Procedure: 
 Measure the absorbance of standard and sample preparations in 1 cm cell on 
suitable UV spectrophotometer at 290 nm, using methanol as blank. Record the 
absorbance. 
Calculation: 
% content of Cyclobenzaprine hydrochloride  
  AT         WS         2           100         50          P                
 ------  X  ------- X -----    X  -------  X ------ X --------  X 100 = ---------% 
   AS        100         50          WT         2           100 
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% content of Cyclobenzaprine = % content of Cyclobenzaprine Hydrochloride            
   Hydrochloride                               ------------------------------------------------------X100 
                                                                                 % Label claim                                                                                                                                                                                                                                                                                  
Where, 
AT = Absorbance of Cyclobenzaprine hydrochloride in sample solution. 
AS = Absorbance of Cyclobenzaprine hydrochloride in standard solution. 
 WS = Weight of Cyclobenzaprine hydrochloride working standard taken in mg. 
  WT = weight of the sample taken in mg. 
P = purity of Cyclobenzaprine hydrochloride working standard used. 
6.8.7 IN-vitro Dissolution studies3
Dissolution (By UV): 
Dissolution parameters: 
 Medium           : 0.1n HCl,  
  Volume            : 900ml 
   Apparatus         : USP Apparatus II (paddle) 
RPM                 : 50 
 Temperature        :  37 ±  0.5 °C 
 Time intervals   : 2nd hour, 4th hour, 8th hour, 12th hour, 16th hours. 
Standard preparation: 
 Transfer about 50 mg of Cyclobenzaprine hydrochloride accurately weighed, 
to a 100ml volumetric flask add 70ml of methanol, sonication for 10 minutes and 
dilute with methanol to volume. Mix and filter. Transfer 2 ml of this solution to a 
100ml volumetric flask, dilute with medium to the volume and mix. 
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Sample preparation: 
 Set the parameters of dissolution apparatus as mentioned above transfer the 
capsules equivalent to 30 mg of Cyclobenzaprine hydrochloride each individual bowls 
and operate the dissolution apparatus, withdraw 10ml of the sample solution after 2nd 
hour, 4th hour, 8th hour, 12th hour, 16th hour from each dissolution jar and replace with 
same volume of dissolution medium previously maintained at 37.0 ± 0.50c. 
Procedure: 
 Measure the absorbance of standard and sample preparation in 1 cm cell on 
suitable UV spectrophotometer at 290 nm, using medium as blank. Record the 
absorbance. 
Calculation: 
% Labelled amount of Cyclobenzaprine hydrochloride dissolved (Dn) 
   AT         WS         2           100         50          P                
 -------  X  ------- X -----    X  -------  X ------ X --------  X 100 = ---------% 
   AS        100         50          WT          2           100 
 
Where, 
AT = Absorbance of Cyclobenzaprine hydrochloride in sample solution. 
 AS = Absorbance of Cyclobenzaprine hydrochloride in standard solution. 
 WS = Weight of Cyclobenzaprine hydrochloride working standard taken in mg. 
 WT = weight of the sample taken in mg 
 P = purity of Cyclobenzaprine hydrochloride working standard used  
Calculation for correction factor: 
 For 2nd Hour  = D2 
For 4th Hour   = D4+CF2 
          For 8th Hour   = D8+CF2 
          For 12th Hour  = D12+CF8+CF4+CF2 
          For 16th Hour  = D16+CF12+CF8+CF4+CF2 
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Procedure:              
Dissolution of the capsules of each batch was carried out using USP 
dissolution type II apparatus using paddle at 50 rpm. The dissolution was studied 
using 900 ml of 0.1N HCl for 16 hours . The temperature was maintained at 37 ± 0.2 
°C. With draw 10ml of the solution from each vessel and replace with equal volume 
of fresh dissolution medium at specific time intervals. Filter the solution through 
What man filter paper and discard first few ml of the filtrate. Dissolution study was 
carried out in pH 0.1 N HCl for 2nd, 4th, 8th, 12th and 16th hours and samples were 
suitably diluted and analyzed for Cyclobenzaprine hydrochloride content at 290 nm 
by UV method. 
Data Treatment of Dissolution Studies: 
1. Dissolution profiles of % DR Vs time were obtained. Amount of drug released 
at 16th hour in 0.1N HCl followed by 2nd, 4th, 8th, 12th, 16th hours were calculated.   
2. Mechanism of drug release was obtained by applying the release data to various 
models like zero order, first order, Higuchi and Korsmeyer equation / Peppa’s 
model  
6.8.8 SCANNING ELECTRON MICROSCOPY (SEM) OF THE OPTIMIZED 
FORMULATION: 
SEM has been used to determine particle size distribution, surface topology, 
texture and to examine the morphology of fractured or sectioned surface. The SEM 
generally used for generating three dimensional surface relief images derived from 
secondary electrons.               
The surface of drug pellets and coated pellets were examined under a scanning 
electron microscopy. The pellets were mounted onto stubs using double sided 
adhesive tape. The mounted samples were sputter coated under an argon atmosphere 
with gold palladium and examined at 15 KV accelerating voltage. 
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6.9. Dissolution Profile Comparison Using Similarity factor f2 and Difference 
factor f1  
The comparison of final optimized formulation compared with the innovator 
product by using similarity and dissimilarity factor, the F1and F2 was respectively 
6.9.1. Calculation of similarity (f2) and dissimilarity (f1) factors: 
  
a) Similarity factor (f2): 
The similarity factor F2 was defined as a logarithmic reciprocal square root 
transformation of ne plus the mean square difference in percent dissolved between the 
tests and reference products. 
This was calculated to compare the test with reference release profiles. It was 
calculated from the mean resolution data according to the following equation. 
F2=50× log{[1+(1/n)
nt=1 (Rt-Tt)2]×100} 
Where,  
n   = number of full point 
Rt = the reference profile at the time points t 
Tt = the test profile at the same point 
The method is more adequate to compare the dissolution profiles when more 
than three or four dissolution time points are available and can be applied if average 
difference between Rt and Tt is >100. 
 
 b) Difference factor or dissimilarity factor (f1): 
Difference factor describes the relative error between two dissolution profiles. 
It is approximately the percentage error between curves. The percent error is zero 
when the test and reference profiles are identical and increases the proportionality 
with the dissimilarity between the two profiles. Dissimilarity factor or difference 
factor (F1) was calculated from the following equation. 
F1= {[ 
nut=1 (Rt-Tt)]/ 
nit=1 Rt]} ×100 
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Table no. 18: Similarity factor range 
S. No. Similarity factor (f2) Significance 
1. <50 Test and reference profiles are dissimilar. 
2. 50 -100 Test and reference profiles are similar. 
3. 100 Test and reference profiles are identical. 
4. >100 The equation yields a negative value. 
6.10 IN-VITRO RELEASE KINETIC MODELS 
The results of in vitro release profile obtained for all the formulations were 
plotted in models of data treatment as follows: -  
1. Zero - order kinetic model - Cumulative % drug released versus time. 
2. First – order kinetic model - Log cumulative percent drug remaining 
versus time. 
3. Higuchi’s model - Cumulative percent drug released versus square root 
of time. 
4. Korsmeyer equation / Peppa’s model - Log cumulative percent drug 
released versus log time. 
 
6.10.1. Zero Order Model:
4 
This model describes the systems where the release rate is independent of the 
concentration of the dissolved species (Shan Yang L., 1998). The dissolution data are 
fitting into the zero order equation 
At = A0 – K0t, 
Where, 
At= Amount of drug released at time‘t’, 
A0= Initial drug concentration, 
K0= Zero order rate constant (hr
-1)    
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When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys Zero – order kinetics and its slope is equal to Zero 
order release constant K0. 
This relation can be used to describe the drug dissolution of several types of 
sustained release pharmaceutical dosage forms, as in the case of some transdermal 
system, as well as matrix tablets with low soluble drugs, coated forms, osmotic 
systems, etc. 
6.10.2. First Order Model: 4 
The first order equation describes the release from systems where the 
dissolution rate is dependent upon the concentration of the dissolving species 
Release behavior generally follows the following first order equation: 
Log C = log C0 – Kt / 2.303                   
Where      
C = the amount of drug dissolved at time‘t’, 
Co = the amount of drug dissolved at t=0 and, 
K = the first order rate constant (hr-1). 
A graph of log amount of drug release vs. time yields a straight line. The 
pharmaceutical dosage forms following this dissolution profile, such as those 
containing water-soluble drugs in porous matrices, release the drugs in a way that is 
proportional to the amount of drug remaining in its interior, in such way, that the 
amount of drug released by unit of time diminishes. 
6.10.3 Higuchi Model:75 
Drug release from the matrix devices by diffusion has been described by 
following Higuchi’s classical diffusion equation 
ft = KH ·t
1/2 
Where 
  ft = fraction of drug released at time ‘t’, 
 KH = Higuchi rate constant. 
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The Higuchi square root equation describes the release from systems where 
the solid is dispersed in an insoluble matrix, and the rate of drug release is related to 
the rate of drug diffusion. 
6.10.4. Korsmeyer equation / Peppa’s model
76
 
To study the mechanism of drug release from the sustained-release matrix 
tablets, the release data were also fitted to the well-known exponential equation 
(Korsmeyer equation/ peppa’s law equation), which is often used to describe the drug 
release behavior from polymeric systems. 
                                    Mt / M = Kt
n 
Where, 
Mt / M = the fraction of drug released at time‘t’. 
K = Constant incorporating the structural and geometrical 
characteristics of      the drug / polymer system. 
 n = Diffusion exponent related to the mechanism of the release. 
Above equation can be simplified by applying log on both sides, 
And we get: -  
Log Mt / M = Log K + n Log t 
Table No.19: MECHANISM OF DRUG RELEASE AS PER KORSMEYER 
EQUATION / PEPPA’S MODEL. 
S. No. n Value Drug release 
1.  < 0.45 Fickian release 
2.  0.45 < n <1.0 Non – Fickian release 
3.  > 1.0 Class II transport 
When the data is plotted as log of drug released versus log time, yields a 
straight line with a slope equal to ‘n’. For Fickian release ‘n’ = 0.45 while for 
anomalous (non-Fickian) transport ‘n’ ranges between 0.45 and 1.0.  
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6.11. ACCELERATED STABILITY STUDY
77, 78
 
Stability of a pharmaceutical preparation can be defined as “the capability of a 
particular formulation in a specific container/closure system to remain within its 
physical, chemical, microbiological, therapeutic and toxicological specifications 
throughout its shelf life.” 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under influence of a variety of 
environmental factors such as temperature, humidity and light, and enables 
recommended storage conditions, re-test periods and shelf-lives to be established. 
Specification which is list of tests, reference to the analytical procedures and 
proposed acceptance criteria, including the concept of different acceptable criteria for 
release and shelf life specifications, is addressed in ICH CS L6AS and IS6B. 
Storage conditions  
Stability samples are stored at 
Accelerated   : 40±2°C/75±5% RH 
Intermediate: 30±2°C/65±5% RH 
Long term     : 25±2°C/60±5% RH 
Testing Intervals for  
Accelerated: Initial, 1, 2, 3 & 6 months 
Long term: Initial, 3, 6, 9, 12, 18, 24 & 36 months.  
Intermediate: Initial, 3, 6, 9 & 12 months. 
The formula of F8 was optimized and selected for evaluation studies. Further 
stability study was done for F8. 
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Evaluation of samples: 
The samples were analyzed for the following parameters, 
• Physical evaluation: 
Appearance: The samples were checked for any change in colour at 
every week. 
• Chemical evaluation: 
Drug content: The samples were checked for drug content. 
Drug release: The samples were subjected to drug release studies. 
  In general significant change for a drug product is defined as 
 A 5% change in assay from its initial value or failure to meet the acceptance 
criteria for when using biological or immunological procedures. 
 Any degradation products exceeding its acceptance criterion. 
 Failure to meet the acceptance criterion for appearance, physical attributes, 
and functionality test. E.g. size, shape and dose delivery per activation 
however some changes in physical attributes may be accepted under 
accelerated condition and as appropriate for the dosage form. 
 Failure to meet the acceptance criterion for pH. 
 Failure to meet the acceptance criterion for dissolution for 12 dosage units.  
            Studies like moisture content, assay, dissolution studies were carried out for a 
period of 2 months. Initial stage, at the end of first month and second month, 
the above said parameters were carried out at 25OC/60%RH, 30OC/65% RH 
and 40OC/75%RH.   
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7. RESULTS & DISCUSSION 
7.1. INNOVATOR DETAILS: 
7.1.1. Description: 
Bonelax capsules are available in two strengths -15 mg, 30mg. 
7.1.2. Dosage form and strength: 
• Bonelax capsules are blue color body, red color cap with “Bonelax 30mg” 
imprinted on the capsule. 
• They are available in 30/100 capsules per container.  
API Characterization: 
 Drug: Cyclobenzaprine Hydrochloride 
Identification (By UV): 
 The UV absorption spectrum obtained with the sample in the assay 
preparation   corresponds to that of the standard preparation as 
obtained in the assay. 
7.1.3. Evaluation: 
Moisture content: 
 Moisture content was determined by KF method and it was found to be 
1.71%. 
 For pellets Characteristics like bulk density, tapped density, 
compressibility index, hausner’s ratio and angle of repose were 
performed. 
Table no. 20: Physical properties 
Bulk density 
(gm/ml) 
Tapped Density 
(gm/ml) 
Compressibility 
Index 
Hausner’s 
Ratio 
Angle of 
repose 
0.830 0.883 6.002 1.063 26 º.62’’ 
 
 Assay:  
 Assay was determined by UV method and it was found to be 99.8%. 
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7.2. Preparation of Calibration curve of Cyclobenzaprine Hydrochloride 
         Calibration curve of Cyclobenzaprine Hydrochloride was determined by 
plotting concentration v/s absorbance at 290 nm. The results were show in table.  
Table No. 21: STANDARD CURVE OF CYCLOBENZAPRINE 
HYDROCHLORIDE IN 0.1N HCl 
Concentration  
in µg/ml 
Absorbance 
at 290nm 
0 0 
5 0.174 
10 0.345 
15 0.523 
20 0.698 
25 0.827 
                                                                                             
 
 
 
 
 
 
 
 
Graph No. 1: Standard curve of Cyclobenzaprine hydrochloride in 0.1 N HCl. 
                                     The Slope                             = 0.013 
The correlation coefficient = 0.998 
  From the standard curve of Cyclobenzaprine Hydrochloride, it was observed 
that the drug obeys Beer’s law in concentration range 5-25 µg/ml in 0.1N HCl 
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7.3. Determination of λmax of  Cyclobenzaprine Hydrochloride :  
                      
 
 
                                                        Wave length 
 
Graph No. 2: UV Spectrum of Cyclobenzaprine Hydrochloride 
  
 The λmax of Cyclobenzaprine Hydrochloride was determined by UV spectrum 
the graph indicates that the maximum absorbance was observed at 289.6nm. The λmax 
value was near to that reported in analytical profile57.           
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7.4. PREFORMULATION STUDIES         
a) Physical Appearance 
 Cyclobenzaprine Hydrochloride was observed visually and it appeared as a 
white crystalline salt 
b) Solubility 
           Solubility studies were conducted and the results are 
Table no. 22: Solubility of drug 
solvent solubility 
water Freely soluble 
Ethanol Freely soluble 
Isopropanol Sparingly soluble 
chloroform Slightly soluble 
Methylene chloride Slightly soluble 
Hydrocarbons Insoluble 
chloroform Insoluble 
 c) Melting Point Determination 
 The Melting point of Cyclobenzaprine Hydrochloride was determined by 
capillary method and it was found to be 2160C while reported melting point range 
215-219oc, which complies with USP standards, indicating purity of the drug sample. 
 d) Physical properties 
 Physical properties of Cyclobenzaprine Hydrochloride like bulk density, 
tapped density, compressibility index, hausner’s ratio and angle of repose result were 
Table No. 23: Physical properties of Cyclobenzaprine Hydrochloride API 
Bulk density 
(gm/ml) 
Tapped Density 
(gm/ml) 
Compressibility 
Index 
Hausner’s 
Ratio 
Angle of 
repose 
0.284 0.426 33.3 1.5 "%&
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7.5. Compatibility Study 
 The drug and excipient combinatoins were taken and the samples were 
observed every week for any color change or lumps formation. For this samples 
stored at 400C/75%RH and the samples were checked at the end of 1,2 and 4th 
weeks.The results of physical observation were shown in table. 
Table No. 24: Compatibility study of drug and excipients 
   40°C / 75% RH (Closed) 
S. No. Drug and Excipients Initial Physical Description 
1st Week 
2nd 
Week 
4th Week 
1 API White crystalline powder * * * 
2 API + Sugar spheres(#24#30) 
Off-white powder contain 
spherical pellets 
* * * 
3 API+ Sugar Powder  Off-white powder * * * 
4 API + Aerosil  Off-white powder * * * 
5 API + Pvpk-30   (1%)  Off-White powder * * * 
6 API + Ethyl cellulose  N-50   Off-White powder * * * 
7 API + HPMC E5   Off-white powder * * * 
8 
API+  Poly ethylene glycol 
6000 
white powder contain 
crystalline material 
* * * 
9 API +  Talc Off white crystalline powder * * * 
10 API + Isopropyl alcohol Off-white thick mass * * * 
11 API +  Purified Water Off-white thick mass. * * * 
12 
API + Sugar spheres +    Ethyl 
cellulose N-50 + HPMC E5 
+Polyethylene glycol 
6000+Pvpk30+Talc+Aerosil 
+Isopropyl alcohol + Sucrose+ 
Purified Water.    
Off-white powder    containing 
lumps 
* * * 
Note:Star mark (*) indicates that there was no interaction between drug and excipients 
at 40°C/75% RH. 
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Spectra No.1: Cyclobenzaprine Hydrochloride. 
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Spectra No.2 : Excipients 
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Spectra no.3: Cylobenzaprine HCl+ Excipients
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Table No. 25: INTERPRETATION OF FT-IR SPECTRA OF 
CYCLOBENZAPRINE HYDROCHLORIDE 
S.No Functional Category Standard IR range 
(cm
-1
) 
Assessment of 
peak in Drug 
(cm
-1
) 
 
1 Skeletal ring stretching vibraton in 
aromatic ring 
1300-1600 1319.35, 1435.09, 
1530.57, 1594.22 
2 C-H stretching in aromatic ring 3000-3100 3060.17 
3 Overtone of C-H bending in 
aromatic ring 
1600-2000 1790.97 
4 C-H Symmetric stretching of         
-CH2 group in tertiary amine 
2660-2820 2635.81 
5 C-H bending vibraton of –CH2 
group in tertiary amine 
1445-1485 1481.38 
6 C-N stretching 1020-1220 1167.94 
7 C-H inplane bending in 
cycloheptane ring 
722 or less 689.57 

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Table No. 26: COMPATABILITY STUDIES 
S.No Functional Category Standard IR range 
(cm
-1
) 
Ranges of peak in 
mixture 
(cm
-1
) 
1 Skeletal ring stretching vibraton in 
aromatic ring 
1300-1600 1345.37, 1439.91, 
1470.77, 1510.22 
2 C-H stretching in aromatic ring 3000-3100 2890.43 
3 Overtone of C-H bending in 
aromatic ring 
1600-2000 1649.19 
4 C-H Symmetric stretching of –
CH2 group in tertiary amine 
2660-2820 2637.74 
5 C-H bending vibraton of –CH2 
group in tertiary amine 
1445-1485 1470.77 
6 C-N stretching 1020-1220 1099.46 
7 C-H inplane bending in 
cycloheptane ring 
722 or less 671.25 

Compatibility studies were performed using FT-IR spectrophotometer to find 
out any physical as well as chemical alteration of the drug characteristics. The IR 
spectrum of pure drug and physical mixture of drug and polymer were studied. From 
the results, it was concluded that there was no interference in the functional group as 
the principle peaks of the Cyclobenzaprine hydrochloride were found to be unaltered 
in the drug-polymer physical mixture, indicating that they were compatible 
chemically. 
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7.7. EVALUATION TESTS 
 Weight variation test: 
 No Significant difference was observed in the weight of individual capsules 
from the average weight. Capsule weights of all batches were found within 
recommended USP limits. 
 Friability test: 
 Friability of all formulations showed %friability less than 1% that indicates 
ability of pellets (capsules) to with stand shocks, which may encountered. 
 Disintegration test: 
 Capsules of all batches Disintegrate within 5 minutes, which indicates 
acceptable limits. 
 Locked length: 
 The values of all capsules locked length observed were within the limits. 
Table No. 28: Evaluation parameters of filled capsules of all Formulations F1-F9 
Evaluation Parameter  
Formulation 
code 
Average Weight 
Variation(n=10) 
(mg) 
Disintegration 
Time(n=5)  
(min) 
Locked 
Length(n=5) 
 (mm) 
F1 178.3±0.351 4.70±0.06 12.5±0.9 
F2 179.0±0.378 4.50±0.04 12.2±0.9 
F3 173.6±0.325 4.40±0.02 11.9±0.7 
F4 177.5±0.348 5.10±0.07 11.7±0.5 
F5 176.6±0.350 4.60±0.05 11.8±0.8 
F6 174.9±0.332 4.90±0.07 11.5±0.6 
F7 174.4±0.329 4.80±0.06 12.3±0.9 
F8 175.7±0.342 4.25±0.02 11.2±0.2 
F9 177.5±0.349 4.58±0.03 11.6±0.7 
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7.7.5. Moisture content test: 
Table No. 29: Moisture content & Friability values of Pellets F1-F9 
 
7.7.6. Assay: 
 The sustained release pellets prepared were evaluated for assay and the results 
for assay of all formulations (F1-F9) were given in the following table 
Table No. 30: Assay results 
Formulation 
 
Assay values (%)  
Specification: 99-101% 
Reference 99.9 
F1 89.8 
F2 95.1 
F3 98.7 
F4 94.5 
F5 104.8 
F6 97.0 
F7 100.7 
F8 99.7 
F9 98.1 
                
 From the above results, the sustained release pellets prepared were compared 
with the reference specification .The assay of formulation F5, F7 & F8 were found to 
be within the limits.                               
S.No Parameter F1 F2 F3 F4 F5 F6 F7       F8   F9 
1 Moisture 
content 
3.2% 2.9% 3.2% 3.6% 3.3% 2.9% 2.3% 1.75% 1.8% 
2 Friability 0.54% 0.50% 0.42% 0.56% 0.61% 0.51% 0.44% 0.33% 0.35% 
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7.7.7. IN-VITRO DRUG RELEASE STUDIES: 
Table No. 31:In-Vitro Release Profile of INNOVATOR: 
Time 
(hours) 
Cumulative % Drug released 
Acid stage (0.1N HCl)  
0 0 
2 27.1 
4 54.9 
8 70.1 
12 76.3 
16 80.4 
 
Table No. 32: Cumulative % Drug release of Formulation F1 to F9 
Time 
hrs 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
2 19.6 37.7 23.7 31.4 49.8 44.6 41.5 27.2 38.1 
4 44.4 62.1 50.3 54.9 66.1 64.8 67.1 51.1 56.3 
8 64.7 70.8 61.9 69.6 79.2 81.2 80.5 68.6 73.5 
12 72.9 79.5 72.8 76.4 85.2 90.0 89.1 77.4 78.4 
16 78.5 80.6 81.4 87.5 96.4 93.8 89.7 84.7 85.7 
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Graph No. 3 : Comparative in-vitro release profiles of  F1-F9 with Innovator 
 Chapter-6 
 Materials and Methods
 Department of Pharmaceutics, The Erode college of Pharmacy & Research institute 

7.6. OPTIMIZED FORMULATION: 
Table No.27: Characteristics of pellets of Formulation F8 
CORE PELLETS RESULTS 
For uncoated Pellets  
Yield ( Limit NLT 97%) 99.6% 
Bulk density 0.726 
Tapped density 0.768 
Compressibility index 5.46 
Hausner’s ratio 1.057 
Angle of repose 26.43 
Sieve analysis (100gm)  
# 18 passed  99g 
# 24 retained 99g 
#18 passed& #24 retained 99g 
For coated Pellets  
Yield ( Limit NLT 97%) 98% 
Bulk density 0.832 
Tapped density 0.885 
Compressibility index 5.98 
Hausner’s ratio 1.06 
Angle of repose 26.56 
Sieve analysis (100gm)  
# 18 passed 98g 
# 22 retained 98g 
#18 passed& #22 retained 98g 
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 A B 
 
  
 C D 
Fig. No:19 
 A – Photograph of prepared pellets  
 B – Microscopic photograph of pellets 
 C - Photograph of prepared capsules 
 D –Shape and Size of pellet (70x) SEM 
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7.9. COMPARATIVE DISSOLUTION STUDIES: 
Table No. 33: Comparative Dissolution Profile of F1 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F1(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 19.6 7.5 56.25 7.5 
 
    59.12 
4 54.90 44.4 10.5 110.25 10.5 f1 value 
8 70.10 64.7 5.4 29.16 5.4 
12 76.30 72.9 3.4 11.56 3.4 
16 80.40 78.5 1.9 3.61 1.9 
 
     9.29 
Total 308.8 280.1 28.7 210.83 28.7  
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Graph No. 4 : Comparative dissolution profile of F2 with innovator. 
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Table No. 34: Comparative Dissolution Profile of  F2 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F2(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 37.7 -10.6 112.36 10.6 
 
   61.09 
4 54.90 62.1 -7.2 51.84 7.2 f1 value 
8 70.10 70.8 -0.7 0.49 0.7 
12 76.30 79.5 -3.2 10.24 3.2 
16 80.40 80.6 -0.2 0.04 0.2 
 
   7.09 
Total 308.8 330.7 -21.9 174.97 21.9  
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Graph. No.  5: Comparative dissolution profile of F2 with innovator. 
 
 Chapter-6 
 Materials and Methods
 Department of Pharmaceutics, The Erode college of Pharmacy & Research institute 

Table No. 35: Comparative Dissolution Profile of  F3 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F3(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 23.7 3.4 11.56 3.4 
 
   65.66 
4 54.90 50.3 4.6 21.16 4.6 f1 value 
8 70.10 61.9 8.2 67.24 8.2 
12 76.30 72.8 3.5 12.25 3.5 
16 80.40 81.4 -1.0 1.0 1.0 
 
   6.70 
Total 308.8 290.1 18.7 113.21 20.7  
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Graph No. 6: Comparative dissolution profile of F3 with innovator. 
 Chapter-6 
 Materials and Methods
 Department of Pharmaceutics, The Erode college of Pharmacy & Research institute 

Table No. 36: Comparative Dissolution Profile of  F4 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F4(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 31.4 -4.3 18.49 4.3 
 
  70.72 
4 54.90 54.9 0.0 0.0 0.0 f1 value 
8 70.10 69.6 0.50 0.25 0.50 
12 76.30 76.4 -0.10 0.01 0.10 
16 80.40 87.5 -3.10 50.41 3.10 
 
   3.89 
Total 308.8 319.8 -11.0 69.16 12.0  
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Graph No. 7 : Comparative dissolution profile of F4 with innovator. 
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Table No. 37: Comparative Dissolution Profile of F5 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F5(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 49.8 -22.70 515.24 22.70 
 
   41.73 
4 54.90 66.1 -11.20 125.44 11.20 f1 value 
8 70.10 79.2 -9.10 82.81 9.10 
12 76.30 85.6 -9.36 86.49 9.36 
16 80.40 96.4 -16.00 256.00 16.00 
 
   22.12 
Total 308.8 377.1 -68.3 1066.03 68.3  
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Graph No.8  : Comparative dissolution profile of F5 with innovator. 
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Table No. 38: Comparative Dissolution Profile of F6 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F6(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 44.6 -17.5 306.25 17.5 
 
   43.62 
4 54.90 64.8 -9.9 98.01 9.9 f1 value 
8 70.10 81.2 -11.10 123.21 11.10 
12 76.30 90.0 -13.7 187.69 13.7 
16 80.40 93.8 -13.4 179.56 13.4 
 
   21.42 
Total 308.8 374.4 -65.6 894.72 65.6  
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Graph No. 9 : Comparative dissolution profile of F6 with innovator. 
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Table No. 39: Comparative Dissolution Profile of F7 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F7(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 41.5 -14.4 207.36 14.4 
 
   46.05 
4 54.90 67.1 -12.2 148.84 12.2 f1 value 
8 70.10 80.5 -10.4 108.16 10.4 
12 76.30 89.1 -12.8 163.84 12.8 
16 80.40 89.7 -9.3 86.49 9.3 
 
    19.14 
Total 308.8 367.9 -59.1 714.69 59.1  
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Graph No. 10 : Comparative dissolution profile of F7 with innovator. 
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Table No. 40: Comparative Dissolution Profile of F8 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F8(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 27.2 0.10 0.01 0.10 
 
   77.05 
4 54.90 51.1 3.8 14.44 3.8   f1 value 
8 70.10 68.6 1.5 2.25 1.5 
12 76.30 77.4 1.10 1.21 1.10 
16 80.40 84.7 4.30 18.49 4.30 
 
    3.50 
Total 308.8 309.0 -0.20 36.40 10.80  
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Graph No.11 : Comparative dissolution profile of F8 with innovator. 
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Table No. 41: Comparative Dissolution Profile of F9 with Innovator: 
Time in 
min 
INNOVATOR 
(R) 
F9(T) Rt-Tt (Rt-Tt)
2
 [Rt-Tt] f2 value 
0 0 0 0 0 0 
2 27.10 38.1 -11.0 121.00 11.0 
 
   61.58 
4 54.90 56.3 -1.40 1.96 1.40   f1 value 
8 70.10 73.5 -3.40 11.56 3.40 
12 76.30 78.4 -2.10 4.41 2.10 
16 80.40 85.7 -5.30 28.09 5.30 
 
    7.51 
Total 308.8 332.0 -23.2 167.02 23.2  
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Graph No. 12 : Comparative dissolution profile of F9 with innovator. 
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In-vitro drug release profiles of all formulations were carried out by using 
0.1N HCl as dissolution medium  for about 16 hours. From the results obtained it was 
observed that F8 with ethyl cellulose N-50 (9.5%) showed 84.7% drug release at the 
end of 16 hours. Whereas different concentrations of ethyl cellulose 8%, 8.5%, 9% 
(F5, F6,F7) showed release about 96.4%, 93.8%, 89.7% in 16 hours. It was found to 
show fast release when compare to innovator and these batches were fail to meet 
similarity factor. The batches F1, F2, F3, F4 with 13.5%, 12%, 11%, 10% of ethyl 
cellulose showed release about 78.5%, 80.6%, 81.4% and 87.5% in 16 hours. It was 
found to show slow release or similar to innovator but failure to meet assay 
specifications. The batch (F9) with 10.5% ethyl cellulose concentration showed the 
release of 85.7% in 16 hours, the release of this found was near to innovator but fail to 
reproducibility of results. Variations in the release concentration of HPMC E5 and 
PEG 6000 affected the drug release rates. From the above results it was found that the 
release of drug from ethyl cellulose N-50 9.5% (F8) gave the better drug release and 
highest similarity factor (77.5) when compare to that other formulations with a 
optimum concentration. On increase in the polymer concentration drug release 
declined while decreasing the polymer concentration drug release fast. The 
formulation F8 was found to give best release with 84.7% (cumulative % drug 
release) in 16 hours 
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7.10. In-vitro RELEASE KINETIC MODELS 




Graph No. 13 : In-vitro release kinetic models of Innovator 
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Graph No. 14 : In-vitro release kinetic models of F1
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Graph No. 15 : In-vitro release kinetic models of F2
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Graph No. 16 : In-vitro release kinetic models of F3
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Graph No.17  : In-vitro release kinetic models of F4
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Graph No. 18 : In-vitro release kinetic models of F5: 
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Graph No.19  : In-vitro release kinetic models of F6: 
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Graph No. 20  : In-vitro release kinetic models of F7: 
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Graph No. 21 : In-vitro release kinetic models of F8 
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Graph No. 22 : In-vitro release kinetic models of F9 
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Table. No.42: In-Vitro Drug Release Kinetic Data 
Mathematical models 
Formulation 
Code First 
Order (R
2
) 
Zero 
Order (R
2
) 
Higuchi 
Model (R
2
) 
Peppa’s 
Model (R
2
) 
‘n’ 
value 
Innovator 0.923 0.797 0.952 0.814 
0.463 
F1 0.964 0.871 0.968 0.922 
0.648 
F2 0.878 0.723 0.928 0.895 
0.550 
F3 0.973 0.862 0.975 0.919 
0.555 
F4 0.972 0.837 0.977 0.946 
0.464 
F5 0.951 0.749 0.947 0.985 
0.302 
F6 0.978 0.764 0.955 0.964 
0.355 
F7 0.922 0.733 0.935 0.909 
0.363 
F8 0.981 0.855 0.979 0.943 
0.528 
F9 0.952 0.787 0.964 0.965 
0.481 
 
The different models, viz. Zero order, first order, higuchi’s equation and 
korsmeyer-peppas equation were used to study the in-vitro release of sustained release 
pellets. The zero order plots of formulations were to be fairly linear as indicated by 
their high regression values. Therefore, it was ascertained that the drug release from 
pellets followed either first-order kinetics. The first order curves alone are not 
sufficient to predict first order since each curve, albeit straight, has a different slope. 
Hence to confirm the exact mechanism of drug release from the polymer films, the 
data’s were computed and graphed according to Higuchi’s equation and korsmeyer-
peppas equation. 
The release of water-soluble drugs was higher than the drugs with lower 
solubility and the mechanism of release was changed with the nature and content 
polymer in the matrix. The type of polymer used imparts a conspicuous on release 
mechanism. 
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The amount released in fixed duration was of more importance and were 
performed with precision and accuracy, the change in amount of polymer was largely 
dependent on the hydrophilic nature of polymers used in the dissolution study and it 
suggested many parameters to control for next batches. On increase in the polymer 
concentration drug release declined.  
First order r2 value for the best batch (F8) was found to be 0.981. Higuchi r2 
Value was found to be 0.979, and peppas r2 value was found to be 0.943 and ‘n’ value 
found to be 0.528 respectively. By the results confirm that order of drug release 
follows first order and the mechanism of drug release from sustained release pellets 
was by Non-Fickian diffusion.                          
Reason for selecting capsules 
    The Cyclobenzaprine Hydrochloride in tablet form of three times dose per a 
day the prior art may cause problems in patients with swallowing difficulty for adults 
and childrens. This drawback is avoided with the use of multi particulate 
formulations, since they may be dispersed in liquids at the movement of the 
administration. 
     It should be kept in mind that pharmaceutical compositions formulated in 
tablets are subject to variations in their physicochemical properties such as hardness, 
disintegration time, and dissolution time and also on dissolution rate due to the 
compression process involved in their production. Such variations are of course 
undesirable in modified release Cyclobenzaprine Hydrochloride capsules, since the 
prediction of the dissolution rate is an extremely important factor for the efficiency of 
the formulation.  
           Finally sustained release multi particulate formulations of Cyclobenzaprine 
Hydrochloride of the invention advantageously provide a better drug release at the 
gastrointestinal tract compared with single tablet formulations and the dosing 
frequency will be reduced. The sustained release capsules will be used mainly to treat 
muscle spasm associated with acute, painful musculoskeletal conditions and may 
improve patient compliance. 
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7.11. ACCELERATED STABILITY STUDIES 
                 Stability studies are carried out as per ICH guidelines for F8 batch of this 
product at 400C/75%RH for about 3 months in stability chamber. 
 
Stability data for Optimized Formulation F8 
Table No. 44: Evaluation parameter values of stability batch. 
 
Time Test Result 
Disintegration time  4.27 min. 
Moisture content 1.76 % 
End of  
1
st
 month 
Assay 99.7% 
Disintegration time 4.28 min. 
Moisture content 1.78 % 
End of  
2
nd
month 
Assay 99.7 % 
Disintegration time 4.28 min. 
Moisture content 1.78 % 
End of  
 3
rd
  month 
Assay 99.6 % 
 
 No Significant change was observed in the assay and disintegration time and 
moisture Content values of Cyclobenzaprine hydrochloride capsules, after a storage 
period of 1st ,2nd, 3rd months at 400 C/75 % RH 
Table No. 45 Dissolution profile of stability batch at 40°C.2ºC/75% ± 5% RH: 
Cumulative Percentage of Drug release at 40°C.2ºC/75% ± 5% RH  
Time (Hrs) 
 
F8  1
st
 month 2
nd
 month 3
rd
 month 
0 0 0 0 0 
2            27.2 27.1 27.0 26.8 
4 51.1 50.9 
50.7 50.6 
8 68.6 68.2 
67.6 67.5 
12 77.4 77.1 76.8 76.5 
16 84.7 84.6 
84.1 83.9 
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Graph : 23 Comparision of In-vitro release of stability batch with F8 
             From the above data it was evident that there was no significant change in the 
physico chemical parameters of Cyclobenzaprine hydrochloride and in-vitro release 
during the stability studies conducted at 40°C & 75%RH for 3 months period when 
compared with initial samples. So, it has show that formulation F8 was found to be 
stable one. 
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8. SUMMARY AND CONCLUSION 
Cyclobenzaprine hydrochloride is a centrally acting skeletal muscle relaxant 
used in the relief of muscle spasm associated with acute, painful musculoskeletal 
conditions, and also used as tranquilizing agent, as anti depressant and in the 
treatment of fibromyalgia. 
 The oral bioavailability of Cyclobenzaprine hydrochloride is 33-55% while its 
dosing frequency is 3-6 hours. Because of such pharmacokinetic 
characteristics the conventional dosage forms of the drug suffer the 
drawbacks of typical immediate release tablets. To overcome these 
drawbacks, sustained release Pellets can be prepared. 
 The active pharmaceutical ingredient Cyclobenzaprine Hydrochloride was 
subjected to preformulation study, which encompasses the “Accelerated drug 
excipient compatibility study”, and the results obtained with selected 
excipients showed good compatibility with Cyclobenzaprine Hydrochloride 
drug. 
 Cyclobenzaprine Hydrochloride coated pellets were formulated by using 
commercially available sugar pellets using the polymers like Ethyl cellulose 
N-50, HPMC E5, PEG 6000 in different proportions for sustaining release. 
The optimization procedures aided in the development of formulation of the 
Cyclobenzaprine Hydrochloride sustained release pellets.  
 The method used for the development of pellets was powder layering 
technique as a simple process. Developed pellets were evaluated for weight 
variation, percentage friability, assay, moisture content, SEM studies and in-
vitro drug release as per official procedure and all formulations gave 
satisfactory results for weight variation, friability and moisture content. 
 Among all formulations F8 gave the highest similarity factor (77.5) and better 
drug release (85.7%) when compare to innovator. F8 was selected as 
optimized formulation. 
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 Drug release profiles were fitted to kinetic modeling like zero order, first 
order, higuchi and peppas models. It was found that the optimized formulation 
(F8) was best fitted to first order and followed non-fickian diffusion. 
 SEM studies confirm that the optimized formulation (pellets) have spherical 
shape and rough surface. 
 The stability of the formulation was determined by “Accelerated stability 
testing” in 40°C ± 2°C / 75% ± 5%RH for 3 months as per ICH guidelines in 
HDPE containers. Finally after the duration, the product was analyzed for 
moisture content, assay, disintegration and dissolution studies. By the stability 
studies, the formulated Cyclobenzaprine Hydrochloride sustained release 
formulation proved to be stable throughout the period of the storage. 
 Sustained release pellets have minimum volume in size, greater surface area 
and more surface activity. The drug loaded pellets release rate was also more. 
And also there was no need of disintegration time for pellets in capsules. 
Because of Small size pellets enter into the systemic circulation in very fast, 
moreover there was no accumulation of drug in the body. 
 Even though Cyclobenzaprine Hydrochloride tablets and capsules available in 
market, the formulation of F8 was shows better results when compare to 
innovator product and the formulation process will be easy, safe and effective. 
Thus from the experimental results, it could be finally concluded that 
the optimized formulated sustained release pellets in capsule of formulation F8 
has relevant drug release rate upto 16 hours rather than innovator and it can be 
used for the relief of muscle spasm associated with acute, painful 
musculoskeletal conditions. 
FUTURE SCOPE: 
• In vivo evaluation of present study. 
• In vitro – In vivo correlation studies. 
• Development of sustained release dosage form of Cyclobenzaprine 
Hydrochloride by using other sustained polymers. 
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